

CORPORATE INFORMATION

Board of Directors

Mrs. Akhter Khalid Waheed	Chairperson & Chief Executive	Executive Director
Mr. Osman Khalid Waheed	President	Executive Director
Mrs. Amna Piracha Khan		Non-Executive Director
Ms. Munize Azhar Peracha		Non-Executive Director
Mr. Farooq Mazhar		Non-Executive Director
Mr. Nihal Cassim		Non-Executive Director
Mr. Shahid Anwar	Nominee of the NIT	Independent Director

Audit Committee

Mr. Shahid Anwar	Chairman
Mrs. Amna Piracha Khan	Member
Mr. Farooq Mazhar	Member
Mr. Nihal Cassim	Member

Investment Committee

Mr. Farooq Mazhar	Chairman
Mr. Osman Khalid Waheed	Member
Mr. Nihal Cassim	Member

HR & Remuneration Committee

Mr. Shahid Anwar	Chairman
Mr. Farooq Mazhar	Member
Mr. Nihal Cassim	Member

Company Secretary/Chief Financial Officer

Syed Ghausuddin Saif

Head of Internal Audit

Mr. Rizwan Hameed Butt

External Auditors

KPMG Taseer Hadi & Co.
Chartered Accountants

Internal Auditors

Ernst & Young Ford Rhodes Sidat Hyder
Chartered Accountants

Bankers

Habib Bank Limited
MCB Bank Limited
Meezan Bank Limited
Bank Al-Habib Limited
Bank Alfalah Limited
Habib Metropolitan Bank Limited
Allied Bank Limited

Legal Advisors

Khan & Piracha

Registered Office

Ferozsons Laboratories Limited
197-A, The Mall
Rawalpindi-46000, Pakistan
Telephone: +92-51-4252155-57
Fax: +92-51-4252153
Email: cs@ferozsons-labs.com

Share Registrar

CorpTec Associates (Pvt.) Limited
503-E, Johar Town, Lahore, Pakistan
Telephone: +92-42-35170336-37
Fax: +92-42-35170338

Factory

P.O. Ferozsons
Amangarh
Nowshera (KPK), Pakistan
Telephone: +92-923-614295, 610159
Fax: +92-923-611302

Head Office

5 K.M - Sunder Raiwind Road
Lahore, Pakistan
Telephone: +92-42-36026700
Fax: +92-42-36026701

Sales Office Lahore

43-AI Noor Building
Bank Square, The Mall,
Lahore, Pakistan
Telephone: +92-42-37358194
Fax: +92-42-37313680

Sales Office Karachi

House No. 9, Block 7/8,
Maqbool Cooperative Housing Society,
Shahrah-e-Faisal, Karachi, Pakistan
Telephone: +92-21-34386852
Fax: +92-21-34386754

(The annual reports can be download from Company's Website: www.ferozsons-labs.com)

KEY OPERATING AND FINANCIAL DATA - FOR THE LAST SIX YEARS

DESCRIPTION	FY 2015	FY 2014	FY 2013	FY 2012	FY 2011	FY 2010
-------------	---------	---------	---------	---------	---------	---------

UNCONSOLIDATED

Operating Results

Revenue - net	(Rs. Million)	4,434	2,535	1,950	1,771	1,437	1,273
Gross Profit	(Rs. Million)	2,016	1,304	1,035	909	730	633
Profit Before Taxation	(Rs. Million)	1,083	567	451	425	363	384
Profit After Taxation	(Rs. Million)	749	418	409	411	327	369

Financial Position

Share Capital	(Rs. Million)	302	302	302	287	250	208
Accumulated Profit	(Rs. Million)	2,401	2,039	1,919	1,649	1,303	1,067
Non Current Assets	(Rs. Million)	1,533	1,367	1,589	1,555	1,538	1,391
Non Current Liabilities	(Rs. Million)	40	46	42	84	88	101
Current Assets	(Rs. Million)	2,856	1,786	1,328	1,055	728	478
Current Liabilities	(Rs. Million)	1,275	392	276	206	234	250

Summary of Cashflow Statement

Cash generated from operations	(Rs. Million)	973	512	284	372	134	227
Net Cash (used in) / generated from investing activities	(Rs. Million)	(223)	(172)	(147)	(223)	(42)	(196)
Net Cash used in Financing activities	(Rs. Million)	(400)	(303)	(128)	(111)	(87)	(38)

Key Financial Ratios

Profitability Ratios

Gross Profit ratio	(%)	45.5	51.4	53.1	51.3	50.8	49.7
Net Profit After Tax to Sales	(%)	16.9	16.5	20.0	23.2	22.8	29.0
Return on Equity	(%)	27.7	17.8	18.4	21.2	21.0	28.9
Return on Capital Employed	(%)	40.6	24.9	20.8	22.4	24.1	29.6

Liquidity Ratios

Current Ratio	(Times)	2.2	4.6	4.8	5.1	3.1	1.9
Quick Ratio/Acid Test Ratio	(Times)	1.3	2.9	2.7	3.1	1.4	0.7

Turnover Ratios

Debtor Turnover Period	(Days)	19	21	26	22	26	13
Inventory Turnover Period	(Days)	187	196	230	179	212	172
Creditors Turnover Period	(Days)	141	82	78	54	41	43
Working Capital Cycle	(Days)	66	135	178	147	198	142
Non-Current Asset Turnover Ratio	(Times)	2.9	1.9	1.2	1.1	0.9	0.9
Operating Cash Flow To Sales Ratio	(%)	21.9	20.2	14.6	21.0	9.3	17.8

Investment/Market Ratios

Earnings per Share Basic & Diluted (Adjusted)	(Rs.)	24.8	13.8	13.5	13.5	10.5	12.7
Cash Dividend per Share	(Rs.)	19.0	12.0	7.0	4.5	2.5	-
Bonus Share Issued	(%)	-	-	-	5.0	15.0	20.0
Price Earning Ratio	(Times)	25.8	16.7	8.2	6.0	9.0	8.2
Market Price per Share	(Rs.)	640	230	111	81	94	104
Cash Dividend Payout Ratio	(%)	76.6	86.8	51.7	33.3	23.9	-

Capital Structure Ratios

Debt To Equity Ratio	(%)	-	-	-	-	-	3.4
Interest Cover	(Times)	78.5	34.2	39.4	54.9	33.6	67.8

CONSOLIDATED


Operating Results

Revenue - net	(Rs. Million)	5,706	3,832	2,879	2,766	2,203	1,537
Gross Profit	(Rs. Million)	2,591	1,828	1,380	1,309	1,129	700
Profit Before Taxation	(Rs. Million)	1,360	761	523	493	508	261
Profit After Taxation	(Rs. Million)	944	552	466	476	426	244


Financial Position

Share Capital	(Rs. Million)	302	302	302	287	250	208
Accumulated Profit	(Rs. Million)	2,811	2,289	2,061	1,744	1,343	1,007
Non Current Assets	(Rs. Million)	1,751	1,642	1,528	1,491	1,473	1,300
Non Current Liabilities	(Rs. Million)	101	122	65	103	122	138
Current Assets	(Rs. Million)	3,474	2,115	1,737	1,529	1,091	682
Current Liabilities	(Rs. Million)	1,456	524	387	440	410	361


REVENUE & GROSS PROFIT (RS. MILLION)




PROFITABILITY RATIOS (%)



INVESTORS' RATIOS




CAPITAL RETURNS RATIOS




MARKET RATIOS



LIQUIDITY & ASSET TURNOVER RATIOS



NON CURRENT ASSETS TO NON CURRENT LIABILITIES (RATIO)



INTEREST COVER (TIMES)



Vertical Analysis

	2015	2014	2013	2012	2011	2010
	-----%-----					
<u>BALANCE SHEET ANALYSIS</u>						
Share Capital and Reserves	86.1	89.1	88.9	85.8	81.2	77.1
Non Current Liabilities	1.5	1.4	3.2	3.9	5.4	9.7
Current Liabilities	12.4	9.5	7.9	10.3	13.4	13.2
Total Equity and Liabilities	100.0	100.0	100.0	100.0	100.0	100.0
Non Current Assets	43.4	54.5	59.6	67.9	74.4	66.5
Current Assets	56.6	45.5	40.4	32.1	25.6	33.5
Total Assets	100.0	100.0	100.0	100.0	100.0	100.0
<u>PROFIT AND LOSS ANALYSIS</u>						
Revenue - net	100.0	100.0	100.0	100.0	100.0	100.0
Cost of sales	54.5	48.6	46.9	48.7	49.2	50.3
Gross Profit	45.5	51.4	53.1	51.3	50.8	49.7
Administrative expenses	4.3	6.3	7.2	7.6	8.0	6.5
Selling and distribution expenses	16.6	23.7	24.9	24.8	22.7	18.4
Other expenses	1.8	1.9	1.7	1.6	1.9	2.3
Other income	2.0	3.5	4.4	7.1	7.7	8.1
Operating Profit	24.7	23.0	23.7	24.5	26.0	30.6
Finance costs	0.3	0.7	0.6	0.4	0.8	0.5
Profit Before Taxation	24.4	22.4	23.1	24.0	25.2	30.2
Taxation	7.5	5.9	2.2	0.8	2.5	1.2
Profit After Taxation	16.9	16.5	21.0	23.2	22.8	29.0

Horizontal Analysis

	2015	2014	2013	2012	2011	2010
	<i>(%) Change from preceding year</i>					
<u>BALANCE SHEET ANALYSIS</u>						
Share Capital and Reserves	13.2	4.4	12.0	19.4	28.0	24.7
Non Current Liabilities	(12.4)	9.8	(50.6)	(4.2)	(12.8)	(34.3)
Current Liabilities	225.3	42.1	34.0	(12.1)	(6.5)	19.9
Total Equity and Liabilities	39.2	8.1	11.7	15.2	21.2	18.3
Non Current Assets	12.2	(14.0)	2.2	1.1	10.5	32.4
Current Assets	59.9	34.5	25.8	45.0	52.3	(9.7)
Total Assets	39.2	8.1	11.7	15.2	21.2	18.3
<u>PROFIT AND LOSS ANALYSIS</u>						
Revenue - net	74.9	30.0	10.1	23.2	12.8	17.3
Cost of sales	96.4	34.6	6.2	22.0	10.3	27.7
Gross Profit	54.6	25.9	13.9	24.5	15.3	8.4
Administrative expenses	20.2	14.4	4.8	16.7	37.8	2.8
Selling and distribution expenses	22.3	23.5	10.6	35.0	39.1	(10.4)
Other expenses	68.3	47.3	14.0	6.9	(6.9)	3.1
Other income	(0.9)	3.5	(31.6)	14.3	7.3	(6.2)
Operating Profit	87.7	26.3	6.8	15.9	(4.2)	20.5
Finance costs	(18.3)	45.4	48.9	(29.1)	93.6	56.5
Profit Before Taxation	90.9	25.8	6.0	17.3	(5.6)	20.1
Taxation	123.3	253.2	202.8	(60.6)	133.3	(75.8)
Profit After Taxation	79.3	2.2	(0.7)	25.8	(11.4)	43.6

Our Vision

We will grow to be the top or second-ranked company in each targeted market segment, on the strength of motivated employees, who see every day as a new opportunity to earn customer trust and credibility.

Mission Statement

We aim to improve the Quality of Life through the ethical promotion and sales of world class medicines at locally relevant prices.
In doing so we will:

Strive to provide best-in-industry returns to our shareholders.

Be the Second to None in Employee Training, Reward and Motivation.

Maintain the Highest Levels of Ethics while focusing on building our portfolio of Prescription Brands.

NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that the **59th** Annual General Meeting of **FEROZSONS LABORATORIES LIMITED** will be held at its Registered Office, 197-A, The Mall, Rawalpindi, on Monday, October 19, 2015, at 12:30 P.M. to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and approve the audited financial statements of the Company together with the Directors' and Auditors' Reports for the year ended June 30, 2015.
2. To approve the payment of final cash dividend of Rs. 15.00 per share i.e. 150% as recommended by the Board of Directors. It is in addition to the interim cash dividend of Rs. 4.00 per share i.e. 40% already paid to the shareholders, thus making a total cash dividend of Rs. 19.00 per share i.e. 190% for the year ended June 30, 2015.
3. To appoint auditors for the year ending June 30, 2016 and fix their remuneration. The present auditors Messrs KPMG Taseer Hadi & Co., Chartered Accountants, retire and being eligible, offer themselves for appointment.
4. To transact any other business with the permission of the Chair.

By the order of board

Rawalpindi
29 August 2015

Syed Ghausuddin Saif
Company Secretary

Notes:

1. Closure of share transfer books:

The share Transfer Books of the Company will remain closed and no transfer of shares will be accepted for registration from 13 October 2015 to 19 October 2015 (both days inclusive). Transfers received in order at the office of our Shares Registrar M/s CorpTec Associates (Pvt.) Limited, 503-E, Johar Town, Lahore., by the close of the business on 12 October 2015 will be in time for the purpose of payment of final dividend to the transferees.

2. Participation in the annual general meeting:

A member entitled to attend and vote at this meeting is entitled to appoint another member/any other person as his/her proxy to attend and vote.

Duly completed instrument of proxy, and the other authority under which it is signed, thereof, must be lodged with the Secretary of the Company at the company's registered office 197-A, The Mall, Rawalpindi at least 48 hours before the time of the Meeting.

3. Change of address:

Any change of address of Members should be immediately notified to the company's share registrars, CorpTec Associates (Pvt.) Limited, 503-E, Johar Town, Lahore.

4. CDC Account Holders will further have to follow the under-mentioned guidelines as laid down by the Securities and Exchange Commission of Pakistan:

A) For attending the Meeting:

- i. In case of individuals, the account holder or sub-account holder and/or the person whose securities are in group account and their registration details are uploaded as per the Regulations, shall authenticate his identity by showing his original computerized national identity card (CNIC) or original passport at the time of attending the meeting.
- ii. In case of corporate entity, the Board of Directors' resolution/power of attorney with specimen signature of the nominee shall be produced at the time of meeting.

B) For appointing Proxies:

- i. In case of individuals, the account holder or sub-account holder and/or person whose securities are in group account and their registration details are uploaded as per the Regulations, shall submit the proxy form accordingly.
- ii. The proxy form shall be witnessed by two persons whose names, addresses and CNIC numbers shall be mentioned on the form.
- iii. Attested copies of CNIC or the passport.
- iv. The proxy shall produce his/her original CNIC or original passport at the time of meeting.
- v. In case of corporate entity, the Board of Directors' resolution/power of attorney with specimen signature shall be submitted along with proxy form to the Company.

5. Conformation for filing status of income tax return for application of revised rates pursuant to the provisions of Finance Act, 2015

All members of the Company are hereby informed that pursuant to the provisions of Finance Act, 2015, Effective July 01, 2015, reforms have been made with regards to deduction of income tax for cash dividend; the rates of deduction of income tax under section 150 of the Income Tax Ordinance, 2001 have been revised as follows:

1	Rate of tax deduction for filer of income tax returns	12.50%
2	Rate of tax deduction for non-filer of income tax returns	17.50%

In case of joint account, each holder is to be treated individually as either a filer or non-filer and tax will be deducted on the basis of shareholding of each joint holder as may be notified by the shareholder, in

writing as follows, to the Company by sending following detail on the registered address of the Company and the members who have deposited their shares into Central Depository Company of Pakistan Limited (CDC) are requested to send a copy of detail regarding tax payment status also to the relevant member stock exchange and CDC if maintaining CDC investor account, or if no notification, each joint holder shall be assumed to have an equal number of shares.

Company Name	Folio/CDS ID/AC #	Total Shares	Principle Shareholder		Joint Shareholder	
			Name and CNIC No.	Shareholding Proportion (No. of Shares)	Name and CNIC No.	Shareholding Proportion (No. of Shares)

The CNIC number / NTN detail is now mandatory and is required for checking the tax status as per the Active Taxpayers List (ATL) issued by the Federal Board of Revenue (FBR) from time to time.

6. Payment of cash dividend electronically (e-dividend)

In accordance with the SECP's Circular No. 18 of 2012 dated June 2012, the shareholders have been given an opportunity to authorize the Company to make payment of cash dividend through direct credit to shareholder's bank account. To opt for the dividend mandate option as stated, the Dividend mandate option as stated, the Dividend Mandate Form is available at Company's website i.e. www.ferozsons-labs.com needs to be duly filled and submitted to the Company on its registered address.

CDC account holders are requested to submit their mandate instruction to the relevant member stock exchange and CDC if maintaining CDC investor account.

7. Submission of computerized national identity card (CNIC) for payment of final cash dividend 2014-15

Members are requested to provide attested photocopies of their CNIC to the Company on its registered address in order to meet the mandatory requirements of SRO 831 (1) 2012 of 5th July 2012 which provides that the dividend warrant should bear the Computerized National Identity Card (CNIC) number of the registered member.

CDC account holders are requested to submit attested copy of their CNIC to the relevant member stock exchange and CDC if maintaining CDC investor account.

8. Circulation of Annual Audited Financial Statements to shareholders through email.

The directive of SECP contained in SRO 787(1) 2014 dated September 8, 2014, whereby Securities and Exchange Commission of Pakistan (SECP) has allowed companies to circulate annual balance sheet, profit and loss account, auditor's report and directors' report etc. (Audited Financial Statements) along with notice of annual general meeting (Notice) to its members through e-mail. Members are requested to provide their email addresses on registered address of the Company.

CDC account holders are requested to submit attested to provide their email addresses to the relevant member stock exchange and CDC if maintaining CDC investor account.

9. Audited accounts of the company for the year ended 30 June 2015 will be provided on the website www.ferozsons-labs.com at least 21 days before the date of Annual General Meeting.

DIRECTOR'S REPORT TO SHAREHOLDERS FOR THE YEAR ENDED 30 JUNE 2015


We are pleased to present the 59th Annual Report which includes the Audited Financial Statements of your Company for the financial year ended 30 June 2015 along with the Consolidated Financial Statements of its subsidiaries, BF Biosciences Limited and the Farmacia retail venture.

Your Company's Individual and Consolidated Financial Results

A summary of the operating results for the year and appropriation of the divisible profits as compared to last year are given below:

	Individual		Consolidated	
	2015	2014	2015	2014
(Rupees in thousands)				
Profit before tax	1,082,539	567,075	1,359,610	760,720
Taxation	(333,948)	(149,547)	(415,822)	(208,557)
Profit after tax	748,591	417,528	943,788	552,163
Profit available for appropriation	2,401,057	2,039,310	2,811,333	2,289,472
Appropriations				
Interim cash dividend for the FY 2015 @ Rs. 4/ share (FY 2014: @ Rs. 3/Share)	(120,747)	(90,561)	(120,747)	(90,561)
Final cash dividend for the FY 2015 @ Rs.15/ share (FY 2014: @ Rs. 9/share)	(452,803)	(271,682)	(452,803)	(271,682)

The year ended 30 June 2015 has been a landmark year for the Company. We have been privileged, through our partnership with Gilead Sciences, Inc., to bring its USFDA-approved breakthrough treatment for Hepatitis C, Sovaldi ®, to patients in Pakistan at a fraction of its international price under the Gilead Access Program. With over 10 million patients infected with the disease, Pakistan has one of the highest burdens of Hepatitis C anywhere in the world. Sovaldi ®, with its superior safety and high cure rates, has helped address a large unmet need for patients of this critical disease.



The Company would like to acknowledge the unprecedented steps taken by Gilead Sciences to reduce the cost of therapy of this breakthrough drug for patients in developing countries like Pakistan, and the efforts of the Federal Ministry of National Health Services and the Drug Regulatory Authority of Pakistan to ensure that Pakistan became the world's first country to receive Sovaldi ® under this special access program.




We are also pleased to inform our shareholders that in addition to its marketing agreement for Sovaldi ®, your Company has entered into a new licensing agreement with Gilead Sciences to locally manufacture an authorized generic of Sovaldi, to further help reduce the cost of treatment and broaden access for patients in Pakistan on an expedited basis.

We have also filed, on behalf of Gilead Sciences, an application

OPERATING EXPENDITURE BREAKUP

■ Cost of sales ■ Administration expenses ■ Selling & distribution expenses




for registration of its break-through combination product, Harvoni® (Sofosbuvir/Ledipasvir), which has a shorter duration of treatment and is particularly effective in the cure of Hepatitis C Genotype I. This genotype affects over a million Pakistanis. Harvoni® was also granted breakthrough status by the FDA and approved in the United States in October, 2014. This product will also be made available in Pakistan at a specially reduced access price.

During the year under review, your Company's consolidated top line increased by nearly Rs. 2 billion to reach Rs. 5,706 Million for the year, a growth of almost 49%. On a stand-alone basis, Net Sales of your Company grew to Rs. 4,434 Million, demonstrating a strong growth of 75% over the figure of Rs. 2,535 Million achieved in the previous year.

The Company's portfolio of prescription products demonstrated a healthy growth during the year. In particular, our cardiology portfolio grew by 21%, exports by 33%, and medical devices by 10%.

While our margins were reduced substantially in percentage terms following Sovaldi's addition to the portfolio, in absolute terms the company benefitted from an increase in gross profit by 55%. Profit from Operations stood at Rs. 1,082 Million, an improvement of 91% over the previous year. The Net Profit After Tax (NPAT) of the Company closed at Rs. 748.591 Million, 79% higher than the figure of Rs. 417.528 Million achieved last year. Consolidated Net Profit of the Company grew by 71% to Rs, 943.788 Million.

WORKING CAPITAL CYCLE (DAYS)



Although in the market sales of subsidiary BF Biosciences have shown a growth, overall sales of subsidiary company have declined slightly during the year under review, mainly due to the deferral of government tenders, which were reflected in the previous year's numbers. Net Sales of BF Biosciences Limited stand at Rs. 1,197 Million for the year, compared to Rs. 1,262 million achieved last year. Owing to improved market sales, the EPS of BF Biosciences Limited increased to Rs. 10.48, an improvement of 50% over the EPS of Rs. 7.00 achieved last year.

Cash and cash equivalent of your Company increased by Rs. 349.8 Million (2014: Rs. 36.9 Million) during the year. Cash flows generated from operating activities at Rs. 973 Million were 90% higher than last year.


Key Operating and Financial Data

A summary of key operating and financial data of the individual and consolidated financial statements for the last six years is annexed.

Earnings Per Share

Based on the net profit for the year ended 30 June 2015 the earnings per share (EPS) stand at Rs. 24.80 per share, compared to prior year adjusted EPS of Rs. 13.83 on capital of Rs. 301.868 Million. Consolidated earnings per-share increased from Rs. 17.41 last year to Rs. 29.97 for the year under review.

EARNING PER SHARE & CASH DIVIDEND PER SHARE (Rs.)



Dividend Announcement

The Directors have recommended a final cash dividend of 150% i.e. Rs. 15.00 per 10- Rupee share. Added to the interim cash dividend of 40% declared earlier during the year, this amounts to a total payout of 190% for the year ended 30 June 2015.

These appropriations will be accounted for in the subsequent financial statements, in compliance with the revised Forth Schedule of the Companies Ordinance, 1984.

Statement of Compliance with the Code of Corporate Governance

Our statement of compliance with the Code of Corporate Governance of Pakistan along with the Auditor's Report thereon forms part of our Annual Report 2015.

Statement of Compliance with Corporate & Financial Reporting Framework

The Board of Directors of your Company is committed to the principal of good corporate management practices. The Management of Company is continuing to comply with the provisions of best practice set out in the Code of Corporate Governance.

As per the requirements of the Code of Corporate Governance, following specific statements are being given hereunder:

- The financial statements prepared by the management of the Company present its state of affairs fairly, the results of its operations, cash flows and changes in equity.
- Proper books of account of the Company have been maintained.
- Appropriate Accounting Policies have been consistently applied in preparation of the Company's financial statements which confirm to the approved accounting standards as applicable in Pakistan.
- The International Financial Reporting Standards (IFRS), as applicable in Pakistan, have been followed in preparation of financial statements and any departure there from has been adequately disclosed and explained.
- The systems of internal controls are sound in design and have been effectively implemented by the management and monitored by the internal auditors as well as Board of Directors and the audit Committee. The Board reviews the effectiveness of established internal controls through the Audit Committee and suggest, whenever required, further improvement in the internal control system.
- There are no significant doubts upon the Company's ability to continue as a going concern.
- There has been no material departure from the best practices of Corporate Governance as detailed in the Listing Regulations.
- The Company does not envisage corporate restructuring or discontinuation of its operations in the foreseeable future.
- All major Government levies in the normal course of business, payable as on 30 June 2015 have been cleared subsequent to the year end.

- During the year, the Company has complied with all applicable provisions, filed all returns/forms and furnished all the relevant particulars as required under the Companies Ordinance, 1984 and allied rules, the Securities and Exchange Commission of Pakistan (SECP) Regulations and listing requirements.
- Director's spouse and Executives of the Company traded in a total of 6,200 shares of the Company during the year. Besides this no other trading in the Company shares was carried out by the Directors, Executives or their spouse(s) and minor children.
- The values of investments of employees' provident fund based on latest audited accounts as of 30 June 2014 are Rs. 266.062 million.

Corporate Social Responsibility (CSR)

During the year under review we have continued following our belief that the success of our business is directly connected with the socio-economic wellbeing of society we live in. Education and Health are perhaps the foremost needs in Pakistan's development.

In line with this philosophy your company supports primary education in Pakistan in collaboration with the Citizen Foundation (TCF), as well as supporting need-based scholarships for undergraduate students at Pakistan's premier university, the Lahore University of Management Sciences (LUMS) through its National Outreach Programme (NOP).

Meetings of the Board of Directors

The information regarding the meetings of the board of directors held during the year ended 30 June 2015 is annexed.

Share Capital and Pattern of Shareholding

The issued, subscribed and paid up capital of the Company as at 30 June 2015 was Rs. 301.868 million. The statement indicating the number of shareholders as on 30 June 2015 and their categories forming the pattern of shareholding as required under the Code of Corporate Governance is annexed.

Risk Management

Our risk management approach is primarily based on understanding, identifying, assessing and then prioritizing risk areas in order to mitigate these risks through evolving operational strategies.

The following are some of the primary risks being faced by our Company:

- **Economic and political risks:** The ever changing economic and political condition in our country has exposed our Company to this risk as well. In order to mitigate this risk the management monitors the financial market conditions and political climate very closely and appropriate actions and strategies are discussed at the management level to counter unfavorable situations.
- **Competition risks:** Due to the weak regulatory controls over illegal and low quality products in the market, the pharmaceutical industry in Pakistan is exposed to unhealthy competition risks. In order to mitigate these risks your Company along with other members of the Pakistan Pharmaceutical Manufacturers Association, is in continuous lobbying for improved Government regulations and policies.

- **Supply chain risks:** The supply chain process plays a pivotal role in day-to-day operations of the Company. We are mitigating this risk through comprehensive production planning and integrating it with the sales forecasting and ordering systems.
- **Information technology risks:** The Company continues to invest in its IT infrastructure keeping in mind its future needs.
- **Financial risks:** These are the risks that are directly attributable to the financial viability of the Company. These have been elaborated in detail in note 37 of the financial statements.

Auditors

The Auditors Messer KPMG Taseer Hadi & Co., Chartered Accountants retire and offer themselves for reappointment for the financial year ending 30 June 2016.

Affirmation

It is our privilege to recognize the tireless efforts of the Company's management and staff at all levels. Without their dedication and hard work, the improved financial and operational results reflected in this report would not have been possible.

We would also like to thank all our stakeholders and business partners for their continued trust in the Company and our products. With their support, we are committed to expanding our efforts to bring the highest quality medical solutions for the benefit of patients in the markets we serve.

On behalf of the Board

Rawalpindi
29 August 2015

(Mrs. Akhter Khalid Waheed)
Chairperson & Chief Executive

DATES AND ATTENDANCE OF BOARD MEETINGS HELD DURING THE YEAR ENDED JUNE 30, 2015

A total of Four Board Meetings were held during the Financial Year 2014-2015 on the following dates:

September 15, 2014

October 24, 2014

February 16, 2015

April 27, 2015

The detail of attendance by Directors is as under:

Director	Number of meetings attended
Mrs. Akhter Khalid Waheed	4
Mr. Osman Khalid Waheed	4
Mrs. Amna Piracha Khan	3
Mrs. Munize Azhar Peracha	4
Mr. Farooq Mazhar	3
Mr. Nihal Cassim	3
Mr. Shahid Anwar	3

Leaves of absence were granted in all cases to Directors.

On behalf of the Board

Rawalpindi
29 August 2015

(Mrs. Akhter Khalid Waheed)
Chairperson and Chief Executive



KPMG Taseer Hadi & Co.
Chartered Accountants
2nd Floor,
Servis House
2-Main Gulberg Jail Road,
Lahore Pakistan

Telephone + 92 (42) 3579 0901-6
Fax + 92 (42) 3579 0907
Internet www.kpmg.com.pk

Review Report to the Members on Statement of Compliance with the Code of Corporate Governance

We have reviewed the enclosed Statement of Compliance with the best practices contained in the Code of Corporate Governance (the Code) prepared by the Board of Directors of **Ferozsons Laboratories Limited** ("the Company") for the year ended 30 June 2015 to comply with the requirements of Listing Regulation no. 35 of Karachi, Lahore and Islamabad Stock Exchanges where the Company is listed.

The responsibility for compliance with the Code is that of the Board of Directors of the Company. Our responsibility is to review, to the extent where such compliance can be objectively verified, whether the Statement of Compliance reflects the status of the Company's compliance with the provisions of the Code and report if it does not and to highlight any non-compliance with the requirements of the Code. A review is limited primarily to inquiries of the Company personnel and review of various documents prepared by the Company to comply with the Code.

As a part of our audit of financial statements we are required to obtain an understanding of the accounting and internal control systems sufficient to plan the audit and develop an effective audit approach. We are not required to consider whether the Board of Director's statement on internal control covers all risks and controls or to form an opinion on the effectiveness of such internal controls, the Company's corporate governance procedures and risks.

The Code requires the Company to place before the Audit Committee, and upon recommendation of the Audit Committee, place before the Board of Directors for their review and approval of its related party transactions distinguishing between transactions carried out on terms equivalent to those that prevail in arm's length transactions and transactions which are not executed at arm's length price and recording proper justification for using such alternate pricing mechanism. We are only required and have ensured compliance of the requirement to the extent of the approval of the related party transactions by the Board of Directors upon recommendation of the Audit Committee. We have not carried out any procedures to determine whether the related party transactions were under taken at arm's length price or not.

Based on our review, nothing has come to our attention which causes us to believe that the Statement of Compliance does not appropriately reflect the Company's compliance, in all material respects, with the best practices contained in the Code as applicable to the Company for the year ended 30 June 2015.

WPM/BA



Further, we highlight below instances of non-compliance with the requirements of the Code as reflected in the paragraph 23 where these are stated in the Statement of Compliance.

S. No.	Paragraph reference	Description
I.	23	The office of Chairperson and Chief Executive of the Company is being held by Mrs. Akhtar Khalid Waheed who is not a non-executive director. However roles and responsibilities of Chairperson and Chief Executive have been separately outlined.

Lahore

Date: 29 August 2015

KPMG Taseer Hadi & Co
Chartered Accountants
(M. Rehan Chughtai)

STATEMENT OF COMPLIANCE WITH THE CODE OF CORPORATE GOVERNANCE

This statement is being presented to comply with the Code of Corporate Governance (Code) contained in Regulation No. 35 of the listing regulations of Karachi, Lahore and Islamabad Stock Exchanges for the purpose of establishing a framework of good governance, whereby a listed company is managed in compliance with the best practices of corporate governance.

The company has applied the principles contained in the Code in the following manner:

1. The Company encourages representation of independent non-executive directors and directors representing minority interests on its Board of Directors. At present the Board includes:

Category	Names
Independent Director	Mr. Shahid Anwar
Executive Directors	Mrs. Akhter Khalid Waheed
	Mr. Osman Khalid Waheed
Non-Executive Directors	Mrs. Amna Piracha Khan
	Mrs. Munize Azhar Peracha
	Mr. Farooq Mazhar
	Mr. Nihal Cassim

The independent director meets the criteria of independence under clause 1 (b) of the Code.

2. The directors have confirmed that none of them is serving as a director on more than seven listed companies, including this Company.
3. All the resident directors of the Company are registered as taxpayers and none of them has defaulted in payment of any loan to a banking company, a DFI or an NBFIs or, being a member of stock exchange, has been declared as a defaulter by that stock exchange.
4. No casual vacancy has occurred on the Board of Directors during the year.
5. The Company has prepared a “Code of Conduct” and has ensured that appropriate steps have been taken to disseminate it throughout the Company along with its supporting policies and procedures.
6. The Board has developed a vision/mission statement, overall corporate strategy and significant policies of the Company. A complete record of particulars of significant policies along with the dates on which they were approved or amended has been maintained.
7. All the powers of the Board have been duly exercised and decisions on material transactions, including appointment and determination of remuneration and terms and conditions of employment of the CEO, other executive and non-executive directors, have been taken by the Board.

8. The meetings of the Board were presided over by the Chairperson and, in her absence, by a director elected by the Board for this purpose and the Board met at least once in every quarter. Written notices of the Board meetings, along with agenda and working papers, were circulated at least seven days before the meetings. The minutes of the meetings were appropriately recorded and circulated.
9. During the year one director of the Company attended Directors' Certification Training Program and obtained certificate from an institute duly approved by the Securities and Exchange Commission of Pakistan.
10. There were no new appointments of the CFO, Company Secretary and Head of Internal Audit during the year, however, all such appointments including their remuneration and terms and conditions of employment are duly approved by the Board.
11. The directors' report for this year has been prepared in compliance with the requirements of the Code and fully describes the salient matters required to be disclosed.
12. The financial statements of the Company were duly endorsed by CEO and CFO before approval of the Board.
13. The directors, CEO and executives do not hold any interest in the shares of the Company other than that disclosed in the pattern of shareholding.
14. The Company has complied with all the corporate and financial reporting requirements of the Code.
15. The Board has formed an Audit Committee. It comprises four members of whom all are non-executive directors and the Chairman of the Committee is an independent director.
16. The meetings of the Audit Committee were held at least once every quarter prior to approval of interim and final results of the Company and as required by the Code. The terms of reference of the Committee have been formed and advised to the Committee for compliance.
17. The Board has formed a Human Resource and Remuneration (HR&R) Committee. It comprises three members, of whom one is independent, two are non-executive directors. The chairman of the Committee is an independent director.
18. The board has outsourced the internal audit function to Ernst & Young Ford Rhodes Sidat Hyder, Chartered Accountants who are considered suitably qualified and experienced for the purpose and are conversant with the policies and procedures of the Company.
19. The statutory auditors of the Company have confirmed that they have been given a satisfactory rating under the quality control review program of the Institute of Chartered Accountants of Pakistan (ICAP), that they or any of the partners of the firm, their spouses and minor children do not hold shares of the Company and that the firm and all its partners are in compliance with International Federation of Accountants (IFAC) guidelines on Code of ethics as adopted by ICAP.
20. The statutory auditors or the persons associated with them have not been appointed to provide other services except in accordance with the listing regulations and the auditors have confirmed that they have observed IFAC guidelines in this regard.

21. The ‘closed period’ prior to the announcement of interim/final results, and business decisions, which may materially affect the market price of Company’s securities, was determined and intimated to directors, employees and stock exchanges.
22. Material/price sensitive information has been disseminated among all market participants at once through Stock Exchanges.
23. We confirm that all other material principles enshrined in the Code have been complied with except that the office of chairperson and chief executive of the Company is being held by Mrs. Akhter Khalid Waheed who is not a non-executive director; however the roles and responsibilities of chairperson and chief executive have been separately outlined.

MRS. AKHTER KHALID WAHEED
Chairperson & Chief Executive



***Unconsolidated Financial Statements
for the Year Ended 30 June 2015***



KPMG Taseer Hadi & Co.
Chartered Accountants
2nd Floor,
Servis House
2-Main Gulberg Jail Road,
Lahore Pakistan

Telephone + 92 (42) 3579 0901-6
Fax + 92 (42) 3579 0907
Internet www.kpmg.com.pk

Auditors' Report to the Members

We have audited the annexed unconsolidated balance sheet of **Ferozsons Laboratories Limited ("the Company")** as at 30 June 2015 and the related unconsolidated profit and loss account, unconsolidated statement of comprehensive income, unconsolidated cash flow statement and unconsolidated statement of changes in equity together with the notes forming part thereof, for the year then ended and we state that we have obtained all the information and explanations which, to the best of our knowledge and belief, were necessary for the purposes of our audit.

It is the responsibility of the Company's management to establish and maintain a system of internal control, and prepare and present the above said statements in conformity with the approved accounting standards and the requirements of the Companies Ordinance, 1984. Our responsibility is to express an opinion on these statements based on our audit.

We conducted our audit in accordance with the auditing standards as applicable in Pakistan. These standards require that we plan and perform the audit to obtain reasonable assurance about whether the above said statements are free of any material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the above said statements. An audit also includes assessing the accounting policies and significant estimates made by management, as well as, evaluating the overall presentation of the above said statements. We believe that our audit provides a reasonable basis for our opinion and, after due verification, we report that:

- a) in our opinion, proper books of account have been kept by the Company as required by the Companies Ordinance, 1984;
- b) in our opinion:
 - i) the unconsolidated balance sheet and unconsolidated profit and loss account together with the notes thereon have been drawn up in conformity with the Companies Ordinance, 1984, and are in agreement with the books of account and are further in accordance with accounting policies consistently applied;
 - ii) the expenditure incurred during the year was for the purpose of the Company's business; and
 - iii) the business conducted, investments made and the expenditure incurred during the year were in accordance with the objects of the Company;

KPMG Taseer Hadi & Co., a Partnership firm registered in Pakistan
and a member firm of the KPMG network of independent member
firms affiliated with KPMG International Cooperative
("KPMG International"), a Swiss entity.

WMC/TA

- c) in our opinion and to the best of our information and according to the explanations given to us, the unconsolidated balance sheet, unconsolidated profit and loss account, unconsolidated statement of comprehensive income, unconsolidated cash flow statement and unconsolidated statement of changes in equity together with the notes forming part thereof conform with approved accounting standards as applicable in Pakistan and give the information required by the Companies Ordinance, 1984, in the manner so required and respectively give a true and fair view of the state of the Company's affairs as at 30 June 2015 and of the profit, its cash flows and changes in equity for the year then ended; and
- d) in our opinion, Zakat deductible at source under the Zakat and Ushr Ordinance, 1980 (XVIII of 1980) was deducted by the Company, and deposited in the Central Zakat Fund established under section 7 of that Ordinance.

Date: 29 August 2015

Lahore



KPMG Taseer Hadi & Co.
Chartered Accountants
(M. Rehan Chughtai)

UNCONSOLIDATED BALANCE SHEET AS

	<i>Note</i>	2015 Rupees	2014 Rupees
EQUITY AND LIABILITIES			
<u>Share capital and reserves</u>			
Authorized share capital 50,000,000 (2014: 50,000,000) ordinary shares of Rs. 10 each		<u>500,000,000</u>	<u>500,000,000</u>
Issued, subscribed and paid up capital	4	301,868,410	301,868,410
Capital reserve	5	321,843	321,843
Accumulated profit		2,401,056,940	2,039,310,336
		<u>2,703,247,193</u>	<u>2,341,500,589</u>
Surplus on revaluation of property, plant and equipment - net of tax	6	371,101,820	373,911,368
<u>Non current liabilities</u>			
Deferred taxation	7	40,137,245	45,796,633
<u>Current liabilities</u>			
Trade and other payables	8	1,250,144,914	388,179,695
Accrued mark-up		10,634	3,645,618
Provision for taxation - net		24,395,580	-
		<u>1,274,551,128</u>	<u>391,825,313</u>
		<u>4,389,037,386</u>	<u>3,153,033,903</u>
Contingencies and commitments	10		

The annexed notes from 1 to 39 form an integral part of these unconsolidated financial statements.

Director

AT 30 JUNE 2015

	<i>Note</i>	2015 Rupees	2014 Rupees
ASSETS			
<u>Non-current assets</u>			
Property, plant and equipment	<i>11</i>	1,287,233,593	1,136,181,457
Intangibles	<i>12</i>	1,040,462	55,381
Long term investments	<i>13</i>	241,708,087	227,255,201
Long term deposits		3,458,825	3,786,100
		1,533,440,967	1,367,278,139
<u>Current assets</u>			
Stores, spare parts and loose tools	<i>14</i>	23,422,301	14,977,483
Stock in trade	<i>15</i>	1,216,591,555	646,619,797
Trade debts - considered good	<i>16</i>	232,931,043	145,664,372
Current portion of long term loan	<i>17</i>	-	100,000,000
Loans and advances - considered good	<i>18</i>	33,559,605	20,239,144
Deposits and prepayments	<i>19</i>	51,496,028	25,094,850
Mark-up accrued		-	4,421,701
Other receivables	<i>20</i>	2,629,658	3,966,227
Short term investments	<i>21</i>	841,000,000	718,578,075
Income tax - net		-	2,073,122
Cash and bank balances	<i>22</i>	453,966,229	104,120,993
		2,855,596,419	1,785,755,764
		4,389,037,386	3,153,033,903

Chairperson & Chief Executive

**UNCONSOLIDATED PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 30 JUNE 2015**

	<i>Note</i>	2015 Rupees	2014 Rupees
Revenue - net	23	4,433,552,219	2,534,928,325
Cost of sales	24	<u>(2,417,655,623)</u>	<u>(1,231,294,748)</u>
Gross profit		2,015,896,596	1,303,633,577
Administrative expenses	25	(192,837,874)	(160,493,145)
Selling and distribution expenses	26	(733,990,364)	(600,132,625)
Finance costs	27	(13,964,279)	(17,085,720)
Other expenses	28	(81,100,687)	(48,180,659)
Other income	29	88,535,346	89,333,419
Profit before taxation		1,082,538,738	567,074,847
Taxation	30	<u>(333,948,031)</u>	<u>(149,546,613)</u>
Profit after taxation		748,590,707	417,528,234
Earnings per share - basic and diluted	31	<u><u>24.80</u></u>	<u><u>13.83</u></u>

The annexed notes from 1 to 39 form an integral part of these unconsolidated financial statements.

Director

Chairperson & Chief Executive

**UNCONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 JUNE 2015**

	2015 Rupees	2014 Rupees
Profit after taxation	748,590,707	417,528,234
Other comprehensive income for the year	-	-
Total comprehensive income for the year	<u>748,590,707</u>	<u>417,528,234</u>

The annexed notes from 1 to 39 form an integral part of these unconsolidated financial statements.

Director

Chairperson & Chief Executive

UNCONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2015

	Share capital	Capital reserve	Accumulated profit	Total
----- Rupees -----				
Balance as at 30 June 2013	301,868,410	321,843	1,918,841,956	2,221,032,209
Total comprehensive income for the year	-	-	417,528,234	417,528,234
Surplus / (deficit) transferred to accumulated profit:				
-on account of incremental depreciation charged during the year - net of tax	-	-	5,570,467	5,570,467
-on account of disposal of fixed assets during the year-net of tax	-	-	(761,911)	(761,911)
	-	-	4,808,556	4,808,556
<i>Transactions with owners of the company:</i>				
-Final dividend for the year ended 30 June 2013 at Rs. 7 per share	-	-	(211,307,887)	(211,307,887)
-Interim dividend for the year ended 30 June 2014 at Rs. 3 per share	-	-	(90,560,523)	(90,560,523)
	-	-	(301,868,410)	(301,868,410)
Balance as at 30 June 2014	301,868,410	321,843	2,039,310,336	2,341,500,589
Total comprehensive income for the year	-	-	748,590,707	748,590,707
Surplus / (deficit) transferred to accumulated profit:				
-on account of incremental depreciation charged during the year - net of tax	-	-	5,654,868	5,654,868
-on account of disposal of fixed assets during the year - net of tax	-	-	(70,038)	(70,038)
	-	-	5,584,830	5,584,830
<i>Transactions with owners of the company:</i>				
-Final dividend for the year ended 30 June 2014 at Rs. 9 per share	-	-	(271,681,569)	(271,681,569)
-Interim dividend for the year ended 30 June 2015 at Rs. 4 per share	-	-	(120,747,364)	(120,747,364)
	-	-	(392,428,933)	(392,428,933)
Balance as at 30 June 2015	301,868,410	321,843	2,401,056,940	2,703,247,193

The annexed notes from 1 to 39 form an integral part of these unconsolidated financial statements.

Director

Chairperson & Chief Executive

UNCONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 30 JUNE 2015

	Note	2015 Rupees	2014 Rupees
<u>Cash flow from operating activities</u>			
Profit before taxation		1,082,538,738	567,074,847
Adjustments for:			
Depreciation		111,238,016	99,501,791
Amortisation		296,050	1,829,328
Gain on disposal of property, plant and equipment		(12,193,695)	(6,545,444)
Finance costs		13,964,279	17,085,720
Gain on re-measurement of short term investments to fair value		-	(36,059,419)
Gain on sale of short term investments		(41,027,036)	(1,278,991)
Mark-up on long term loan		(5,367,897)	(26,609,083)
Share in profit of Farmacia		(14,452,886)	(2,523,125)
Provision for Worker's Profit Participation Fund		57,600,151	30,455,148
Provision for Central Research Fund		11,636,394	6,152,555
Provision for Worker's Welfare Fund		11,864,141	11,572,956
		133,557,517	93,581,436
Cash generated from operations before working capital changes		1,216,096,255	660,656,283
Effect on cash flow due to working capital changes (Increase) / decrease in current assets			
Stores, spare parts and loose tools		(8,444,818)	(6,288,219)
Advances, deposits, prepayments and other receivables		(38,385,070)	5,469,489
Stock in trade		(569,971,758)	(80,029,197)
Trade debts - considered good		(87,266,671)	(6,573,442)
		(704,068,317)	(87,421,369)
Increase in current liabilities			
Trade and other payables		822,043,954	87,211,216
Cash generated from operations		1,334,071,892	660,446,130
Taxes paid		(310,363,435)	(113,782,764)
Worker's Profit Participation Fund paid		(33,250,628)	(22,610,064)
Worker's Welfare Fund paid		(11,572,956)	(7,945,921)
Central Research Fund paid		(6,152,555)	(4,554,728)
Long term deposits		327,275	-
Net cash generated from operating activities		973,059,593	511,552,653
<u>Cash flow from investing activities</u>			
Acquisition of property, plant and equipment		(266,687,745)	(158,702,698)
Acquisition of intangibles		(991,131)	-
Proceeds from sale of property, plant and equipment		16,301,288	13,553,863
Interest income received on long term loan		9,789,598	30,953,247
Recovery of long term loan		100,000,000	225,000,000
Acquisition of short term investments - net		(81,394,889)	(282,386,676)
Net cash used in investing activities		(222,982,879)	(171,582,264)
<u>Cash flow from financing activities</u>			
Repayment of short term borrowings		-	(695,869)
Finance cost paid		(17,599,263)	(12,514,948)
Dividend paid		(382,632,215)	(289,882,690)
Net cash used in financing activities		(400,231,478)	(303,093,507)
Net increase in cash and cash equivalents		349,845,236	36,876,882
Cash and cash equivalents at beginning of the year		104,120,993	67,244,111
Cash and cash equivalents at end of the year	22	453,966,229	104,120,993

The annexed notes from 1 to 39 form an integral part of these unconsolidated financial statements.

Director

Chairperson & Chief Executive

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2015

1 Reporting entity

Ferozsons Laboratories Limited (“the Company”) was incorporated as a private limited company on 28 January 1954 and was converted into a public limited company on 08 September 1960. The Company is listed on the Karachi, Lahore and Islamabad stock exchanges and is primarily engaged in the imports, manufacture and sale of pharmaceuticals products. Its registered office is situated at 197-A, The Mall, Rawalpindi and the factory is located at Amangarh, Nowshera, Khyber Pakhtun Khwa.

2 Basis of preparation

2.1 Separate financial statements

These financial statements are the separate financial statements of the Company in which investments in subsidiaries and associates are accounted for on the basis of direct equity interest rather than on the basis of reported results and net assets of the investee. Consolidated financial statements of the Company are prepared separately.

The Company has following major investments:

Name of the company	Shareholding
<u>Subsidiaries</u>	
- BF Biosciences Limited	80%
- Farmacia	98%

2.2 Statement of compliance

These unconsolidated financial statements have been prepared in accordance with the approved accounting standards as applicable in Pakistan. Approved accounting standards comprise of such International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board as notified under the provisions of the Companies Ordinance, 1984, provisions of and directives issued under the Companies Ordinance, 1984. In case, the requirements differ, the provisions or directives of the Companies Ordinance, 1984, shall prevail.

2.3 Standards, interpretations and amendments to published approved accounting standards

2.3.1 Standards, amendments or interpretations which became effective during the year

During the year certain amendments to standards or new interpretations became effective. However, the amendments or interpretations did not have any material effect on the unconsolidated financial statements of the Company.

2.3.2 New / revised accounting standards, amendments to published accounting standards, and interpretations that are not yet effective

The following standards, amendments and interpretations of approved accounting standards

will be effective for accounting periods beginning on or after 01 July 2015. The Company either does not expect to have any effect or any material / significant effect on its accounting policy due to their application when become effective other than increase in disclosures, if any.

- Amendments to IAS 38 Intangible Assets and IAS 16 Property, Plant and Equipment (effective for annual periods beginning on or after 1 January 2016) introduce severe restrictions on the use of revenue-based amortization for intangible assets and explicitly state that revenue-based methods of depreciation cannot be used for property, plant and equipment. The rebuttable presumption that the use of revenue-based amortisation methods for intangible assets is inappropriate can be overcome only when revenue and the consumption of the economic benefits of the intangible asset are ‘highly correlated’, or when the intangible asset is expressed as a measure of revenue. The amendments are not likely to have an impact on the Company’s unconsolidated financial statements.
- IFRS 10 ‘Consolidated Financial Statements’ – (effective for annual periods beginning on or after 1 January 2015) replaces the part of IAS 27 ‘Consolidated and Separate Financial Statements’. IFRS 10 introduces a new approach to determining which investees should be consolidated. The single model to be applied in the control analysis requires that an investor controls an investee when the investor is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. IFRS 10 has made consequential changes to IAS 27 which is now called ‘Separate Financial Statements’ and will deal with only separate financial statements. Certain further amendments have been made to IFRS 10, IFRS 12 and IAS 28 clarifying the requirements relating to accounting for investment entities and would be effective for annual periods beginning on or after 1 January 2016. The management is currently considering the effect of the new standard.
- IFRS 11 ‘Joint Arrangements’ (effective for annual periods beginning on or after 1 January 2015) replaces IAS 31 ‘Interests in Joint Ventures’. Firstly, it carves out, from IAS 31 jointly controlled entities, those cases in which although there is a separate vehicle, that separation is ineffective in certain ways. These arrangements are treated similarly to jointly controlled assets/ operations under IAS 31 and are now called joint operations. Secondly, the remainder of IAS 31 jointly controlled entities, now called joint ventures, are stripped of the free choice of using the equity method or proportionate consolidation; they must now always use the equity method. IFRS 11 has also made consequential changes in IAS 28 which has now been named ‘Investment in Associates and Joint Ventures’. The amendments requiring business combination accounting to be applied to acquisitions of interests in a joint operation that constitutes a business are effective for annual periods beginning on or after 1 January 2016. The adoption of this standard is not likely to have an impact on the Company’s unconsolidated financial statements.
- IFRS 12 ‘Disclosure of Interests in Other Entities’ (effective for annual periods beginning on or after 1 January 2015) combines the disclosure requirements for entities that have interests in subsidiaries, joint arrangements (i.e. joint operations or joint ventures), associates and/or unconsolidated structured entities, into one place. The adoption of this standard is not likely to have an impact on the Company’s unconsolidated financial statements.
- IFRS 13 ‘Fair Value Measurement’ (effective for annual periods beginning on or after 1 January 2015) defines fair value, establishes a framework for measuring fair value and sets out disclosure

requirements for fair value measurements. IFRS 13 explains how to measure fair value when it is required by other IFRSs. It does not introduce new fair value measurements, nor does it eliminate the practicability exceptions to fair value measurements that currently exist in certain standards. The adoption of this standard is not likely to have an impact on the Company's unconsolidated financial statements.

- Amendments to IAS 27 'Separate Financial Statements' (effective for annual periods beginning on or after 1 January 2016). The amendments to IAS 27 will allow entities to use the equity method to account for investments in subsidiaries, joint ventures and associates in their separate financial statements. The adoption of the amended standard is not likely to have an impact on the Company's unconsolidated financial statements.
- Agriculture: Bearer Plants [Amendments to IAS 16 and IAS 41] (effective for annual periods beginning on or after 1 January 2016). Bearer plants are now in the scope of IAS 16 Property, Plant and Equipment for measurement and disclosure purposes. Therefore, a company can elect to measure bearer plants at cost. However, the produce growing on bearer plants will continue to be measured at fair value less costs to sell under IAS 41 Agriculture. A bearer plant is a plant that: is used in the supply of agricultural produce; is expected to bear produce for more than one period; and has a remote likelihood of being sold as agricultural produce. Before maturity, bearer plants are accounted for in the same way as self-constructed items of property, plant and equipment during construction. The adoption of the amended standard is not likely to have an impact on the Company's unconsolidated financial statements.
- Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendments to IFRS 10 and IAS 28) [effective for annual periods beginning on or after 1 January 2016]. The main consequence of the amendments is that a full gain or loss is recognised when a transaction involves a business (whether it is housed in a subsidiary or not). A partial gain or loss is recognised when a transaction involves assets that do not constitute a business, even if these assets are housed in a subsidiary. The adoption of these amendments is not likely to have an impact on the Company's unconsolidated financial statements.

Annual Improvements 2012-2014 cycles (amendments are effective for annual periods beginning on or after 1 January 2016). The new cycle of improvements contain amendments to the following standards:

- o IFRS 5 Non-current Assets Held for Sale and Discontinued Operations. IFRS 5 is amended to clarify that if an entity changes the method of disposal of an asset (or disposal group) i.e. reclassifies an asset from held for distribution to owners to held for sale or vice versa without any time lag, then such change in classification is considered as continuation of the original plan of disposal and if an entity determines that an asset (or disposal group) no longer meets the criteria to be classified as held for distribution, then it ceases held for distribution accounting in the same way as it would cease held for sale accounting.
- o IFRS 7 'Financial Instruments- Disclosures'. IFRS 7 is amended to clarify when servicing arrangements are in the scope of its disclosure requirements on continuing involvement in transferred financial assets in cases when they are derecognized in their entirety. IFRS 7 is also amended to clarify that additional disclosures required by 'Disclosures: Offsetting Financial Assets and Financial Liabilities (Amendments to IFRS7)' are not specifically required for

inclusion in condensed interim financial statements for all interim periods.

- o IAS 19 ‘Employee Benefits’. IAS 19 is amended to clarify that high quality corporate bonds or government bonds used in determining the discount rate should be issued in the same currency in which the benefits are to be paid.
- o IAS 34 ‘Interim Financial Reporting’. IAS 34 is amended to clarify that certain disclosures, if they are not included in the notes to interim financial statements and disclosed elsewhere should be cross referred.

2.4 Basis of measurement

These unconsolidated financial statements have been prepared on the historical cost convention except for certain items of property, plant and equipment that are stated at revalued amounts and investment in listed securities and financial instruments that are stated at their fair values. The methods used to measure fair values are discussed further in their respective policy notes.

2.5 Functional and presentation currency

These unconsolidated financial statements are presented in Pakistani Rupee (“Rs.”) which is the Company’s functional currency. All financial information presented in Rupees has been rounded off to the nearest rupee, unless otherwise stated.

2.6 Use of estimates and judgements

The preparation of financial statements in conformity with the approved accounting standards requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making judgment about carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on a continuous basis. Revisions to accounting estimates are recognized in the period in which estimates are revised if the revision affects only that period, or in the period of the revision and any future periods affected.

Judgments made by the management in the application of approved accounting standards that have significant effect on the unconsolidated financial statements and estimates with a significant risk of material adjustment in the next year are discussed in the ensuing paragraphs.

2.6.1 Property, plant and equipment

The Company reviews the useful lives and residual value of property, plant and equipment on regular basis. Any change in the estimates in future years might affect the carrying amounts of the respective items of property, plant and equipment with a corresponding effect on the depreciation charge and impairment.

2.6.2 Intangibles

The Company reviews the rate of amortisation and value of intangible assets for possible impairment, on an annual basis. Any change in the estimates in future years might affect the carrying amounts of intangible assets with a corresponding affect on the amortisation charge and impairment.

2.6.3 Stores, spare parts, loose tools and stock in trade

The Company reviews the stores, spare parts, loose tools and stock in trade for possible impairment on an annual basis. Any change in the estimates in future years might affect the carrying amounts of the respective items of stores, spare parts and loose tools and stock in trade with a corresponding affect on the provision and net realizable value.

Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and estimated costs necessary to make the sale.

2.6.4 Provision against trade debts, advances and other receivables

The Company reviews the recoverability of its trade debts, advances and other receivables to assess impairment and provision required there against on annual basis.

2.6.5 Provisions

Estimates of the amount of provisions recognized are based on current legal and constructive requirements. Because actual outflows can differ from estimates due to changes in laws, regulations, public expectations, technology, prices and conditions, and can take place many years in the future, the carrying amounts of provisions are regularly reviewed and adjusted to take account of such changes.

2.6.6 Impairment

The management of the Company reviews carrying amounts of its assets including receivables and advances and cash generating units for possible impairment and makes formal estimates of recoverable amount if there is any such indication.

2.6.7 Fair value of investments

The Company regularly reviews the fair value of investments, the estimate of fair values are directly linked to market value. Any change in estimate will effect the carrying value of investments with the corresponding impact on profit and loss account.

2.6.8 Taxation

The Company takes into account the current income tax laws and decisions taken by appellate authorities. Instances where the Company's view differs from the view taken by the income tax department at the assessment stage and the Company considers that its view on items of material nature is in accordance with law, the amounts are shown as contingent liabilities.

3 Significant accounting policies

3.1 Employee benefits

Salaries, wages and benefits are accrued in the period in which the associated services are rendered by employees of the Company and measured on an undiscounted basis. The accounting policy for employee retirement benefits is described below:

3.1.1 Staff provident fund

The Company operates a recognized provident fund as a defined contribution plan for employees who fulfil conditions laid down in the trust deed. Provision is made in the financial statements for the amount payable by the Company to the fund in this regard. Contribution is made to the fund equally by the Company and the employees at the rate of 10% of basic salary.

3.1.2 Compensated absences

The Company provides for compensated absences for its employees on unavailed balance of leave in the period in which leave is earned.

3.2 Taxation

Income tax expense comprises current and deferred tax. Income tax expense is recognized in the profit and loss account, except to the extent that it relates to items recognized directly in other comprehensive income or equity, in which case it is recognized in other comprehensive income or equity respectively.

3.2.1 Current

Provision for current taxation is based on taxable income at the enacted or substantively enacted rates of taxation after taking into account available tax credits and rebates, if any. The charge for current tax includes adjustments to charge for prior years, if any.

3.2.2 Deferred

Deferred tax is recognized using balance sheet method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using the enacted or substantively enacted rates of taxation.

The Company recognizes a deferred tax asset to the extent that it is probable that taxable profits for the foreseeable future will be available against which the asset can be utilized. Deferred tax assets are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

3.3 Property, plant and equipment, depreciation and capital work in progress

3.3.1 Owned

Property, plant and equipment of the Company other than freehold land, building and plant and machinery are stated at cost less accumulated depreciation and impairment loss, if any. Cost in relation to property, plant and equipment comprises acquisition and other directly attributable costs. Building, plant and machinery are stated at revalued amount less accumulated depreciation and impairment loss, if any. Freehold land is stated at revalued amount. Revaluation is carried out every five years unless earlier revaluation is necessitated.

Depreciation is provided on a straight line basis and charged to profit and loss account to write off the depreciable amount of each asset, except for freehold land, over its estimated useful life at the rates specified in note 11 to these financial statements. Depreciation on depreciable assets is commenced from the date asset is available for use up to the date when asset is retired.

Surplus arising on revaluation is credited to the surplus on revaluation of fixed asset account. Deficit, if any, arising on subsequent revaluation of property, plant and equipment is adjusted against the balance in the above mentioned surplus account. The surplus on revaluation of fixed assets to the extent of incremental depreciation charged on the related assets is transferred to equity, net of related deferred tax.

The cost of replacing part of an item of property, plant and equipment is recognised in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the day-to-day servicing of property, plant and equipment are recognised in profit or loss as incurred.

Gain and loss on sale of an item of property, plant and equipment are determined by comparing the proceeds from sale with the carrying amount of property, plant and equipment, and are recognised net within “other income / other expenses” in profit or loss account. When revalued asset is sold, the amount included in the surplus on revaluation of property, plant and equipment, net of deferred tax, is transferred directly to equity.

3.3.2 Capital work in progress

Capital work in progress is stated at cost less identified impairment loss, if any, and includes the expenditures on material, labour and appropriate directly attributable overheads. These costs are transferred to property, plant and equipment as and when assets are available for their intended use.

3.4 Intangibles

Expenditure incurred on intangible asset is capitalized and stated at cost less accumulated amortisation and any identified impairment loss. Intangible assets with finite useful life are amortised using the straight-line method over the estimated useful life of three years. Amortisation of intangible assets is commenced from the date an asset is capitalized.

3.5 Financial instruments

All the financial assets and financial liabilities are recognized at the time when the Company becomes a party to the contractual provisions of the instruments. The Company de-recognizes a financial asset or a portion of financial asset when, and only when, the enterprise loses control of the contractual rights that comprise the financial asset or portion of financial asset. A financial liability or part of financial liability is de-recognized from the balance sheet, when and only when, it is extinguished i.e. when the obligation specified in the contract is discharged, cancelled or expired. Any gain or loss on the recognition or de-recognition of the financial assets and liabilities is included in the profit and loss account currently.

Significant financial assets include long term deposits, short term investments, trade debts, loans and advances, other receivables, mark-up accrued and cash and bank balances.

Significant financial liabilities are classified according to the substance of the contractual agreements entered into. Significant financial liabilities include trade and other payables.

3.6 Financial assets and liabilities

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. All financial assets and liabilities are initially measured at cost, which is the fair value of the consideration given and received respectively. These financial assets and liabilities are subsequently measured at fair value, amortised cost or cost, as the case may be. The particular measurement methods adopted are disclosed in the individual policy statements associated with each item.

3.7 Investments

3.7.1 Investments in subsidiaries

Investments in subsidiaries are initially valued at cost. At subsequent reporting dates, the Company reviews the carrying amount of the investment to assess whether there is any indication that such investments have suffered an impairment loss. If any such indication exists, the recoverable amount is estimated in order to determine the extent of the impairment loss, if any.

3.7.2 Investments at fair value through profit or loss

These include investments classified as held for trading or upon initial recognition are designated by the Company at fair value through profit or loss. Investments which are acquired principally for the purpose of generating a profit from short term fluctuations in price or dealer's margin are classified as held for trading. After initial recognition, these are stated at fair values with any resulting gains and losses recognized directly in income. Fair value of investments is their quoted bid price at the balance sheet date. Transaction costs are charged to income currently.

3.7.3 Loans and receivables

These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. At initial recognition these financial assets are measured at fair value plus transaction costs that are directly attributable to the acquisition of the financial asset. After initial recognition, these are measured at amortized cost using the effective interest rate method less impairment loss, if any.

3.7.3.1 Trade debts

Trade debts are stated initially at the fair value, subsequent to initial recognition. These are stated at their amortised cost as reduced by appropriate provision for impairment, known impaired receivables are written off, while receivables considered doubtful are fully provided for.

The allowance for doubtful accounts is based on the Company's assessment at the collectability of counterparty accounts. The Company regularly reviews its trade debts that remain outstanding past their applicable payment terms and establishes allowance and potential write-offs by considering facts such as historical experience, credit quality, age of the accounts receivable balances and current economic conditions that may effect customers ability to pay.

3.8 Settlement date accounting

Regular way purchases and sales of financial assets are recognized on trade dates.

3.9 Trade and other payables

Liabilities for trade and other amounts payable are carried at cost which is the fair value of the consideration to be paid in future for goods or services received.

3.10 Offsetting of financial assets and financial liabilities

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet only when the Company has a legally enforceable right to set off the recognized amounts and intends to either settle on a net basis or realize the asset and settle the liability simultaneously.

3.11 Provisions

Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate of the obligation can be made. However, provisions are reviewed at each balance sheet date and adjusted to reflect current best estimate.

3.12 Foreign currency

All monetary assets and liabilities in foreign currencies are translated into rupees at exchange rates prevailing at the balance sheet date. Transactions in foreign currencies are translated into rupees at exchange rates prevailing at the date of transaction. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated into rupees at exchange rates prevailing at the date of transaction. Non-monetary assets and liabilities denominated in foreign currency that are stated at fair value are translated into rupees at exchange rates prevailing at the date when fair values are determined. Exchange gains and losses are included in the income currently.

3.13 Stores, spare parts and loose tools

Stores, spare parts and loose tools are valued at lower of cost and net realizable value. Cost is determined on weighted average cost basis. Items in transit are valued at cost comprising invoice value plus other incidental charges incurred thereon.

3.14 Stocks in trade

Stocks are valued at the lower of average cost and net realizable value. Cost is determined as follows:

Raw material	-	at moving average cost
Work in process	-	at weighted average cost of purchases and
Finished goods	-	applicable manufacturing expenses - for those purchased for onward sale are carried at moving average cost

Cost comprises of purchase and other costs incurred in bringing the material to their present location and condition. Net realizable value signifies the estimated selling price in the ordinary course of business less estimated costs necessarily to be incurred in order to make a sale.

3.15 Cash and cash equivalents

For the purpose of cash flow, cash and cash equivalents mainly comprise cash and bank balances which are stated in the balance sheet at cost.

3.16 Revenue recognition

Revenue represents the fair value of the consideration received or receivable for sale of pharmaceutical products, net of discounts. Revenue is recognized when the goods are dispatched and title passes to the customer, it is probable that the economic benefits associated with the transaction will flow to the Company and the amount of revenue, and the associated cost incurred, or to be incurred, can be measured reliably.

3.17 Borrowing costs

Mark-up, interest and other direct charges on borrowings are capitalized to the related qualifying asset till substantially all the activities necessary to prepare the qualifying asset for its intended use are complete. All other mark-up, interest and related charges are charged to the profit and loss account as finance cost.

3.18 Other income

Other income comprises interest income on funds invested, dividend income, exchange gain and changes in the fair value of financial asset at fair value through profit or loss. Income on bank deposits is accrued on a time proportion basis by reference to the principal outstanding and the applicable rate of return. Foreign currency gains and losses are reported on a net basis.

Dividend income relating to post acquisition profit is recognized when the right to receive is established.

Gains and losses on sale of investments are accounted for on sale of security.

3.19 Impairment

Financial assets

A financial asset is assessed at each reporting date to determine whether there is any objective evidence that it is impaired. Individually significant financial assets are tested for impairment on an individual basis. The remaining financial assets are assessed collectively in groups that share similar credit risk characteristics. A financial asset is considered to be impaired if objective evidence indicates that one or more events have had a negative effect on the estimated future cash flows of the asset.

An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount, and the present value of the estimated future cash flows discounted at the original effective interest rate. Impairment loss in respect of a financial asset measured at fair value is determined by reference to that fair value. All impairment losses are recognized in profit and loss account. An impairment loss is reversed if the reversal can be related objectively to an event occurring after the impairment loss was recognized. An impairment loss is reversed only to the extent that the financial asset's carrying amount after the reversal does not exceed the carrying amount that would have been determined, net of amortization, if no impairment loss had been recognized.

Non financial assets

The carrying amount of the Company's non-financial assets, other than inventories and deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated. The recoverable amount of an asset or cash generating unit is the greater of its value in use and its fair value less cost to sell. In assessing value in use, the estimated future cash flows

are discounted to their present values using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or cash generating unit.

An impairment loss is recognized if the carrying amount of the assets or its cash generating unit exceeds its estimated recoverable amount. Impairment losses are recognized in profit and loss account. Impairment losses recognized in respect of cash generating units are allocated to reduce the carrying amounts of the assets in a unit on a pro rata basis. Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to that extent that the asset's carrying amount after the reversal does not exceed the carrying amount that would have been determined, net of depreciation and amortization, if no impairment loss had been recognized.

3.20 Earnings per share (EPS)

Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Company by weighted average number of ordinary shares outstanding during the year.

3.21 Dividend distribution

Dividend is recognized as a liability in the period in which it is approved.

	2015 Rupees	2014 Rupees
4 Issued, subscribed and paid up capital		
1,441,952 (2014: 1,441,952) ordinary shares of Rs. 10 each fully paid in cash	14,419,520	14,419,520
119,600 (2014: 119,600) ordinary shares of Rs. 10 each issued in lieu of NWF Industries Limited and Sargodha Oil and Flour Mills Limited since merged	1,196,000	1,196,000
28,625,289 (2014: 28,625,289) ordinary shares of Rs. 10 each issued as fully paid bonus shares	<u>286,252,890</u>	<u>286,252,890</u>
	<u>301,868,410</u>	<u>301,868,410</u>

KFW Factors (Private) Limited, an associated company held 8,286,942 (2014: 8,286,942) ordinary shares of Rs. 10 each of the Company.

5 Capital reserve

This represents capital reserve arose on conversion of shares of NWF Industries Limited and Sargodha Oil & Flour Mills Limited, since merged.

	2015 Rupees	2014 Rupees
6 Surplus on revaluation of property, plant and equipment - net of tax		
Surplus on revaluation of property, plant and equipment as at 1 July	395,088,740	402,374,432
Surplus transferred to equity on account of incremental depreciation charged during the year net of deferred tax	(5,654,868)	(5,570,467)
Related deferred tax liability	(2,785,234)	(2,869,635)
	(8,440,102)	(8,440,102)
Deficit transferred to equity:		
- on account of disposal of assets during the year net of deferred tax	70,038	761,911
- Related deferred tax liability	34,497	392,499
	104,535	1,154,410
	386,753,173	395,088,740
Related deferred tax liability:		
- On revaluation as at 1 July	(21,177,372)	(23,654,508)
- Transferred		
- on account of incremental depreciation charged during the year	2,785,234	2,869,635
- on account of disposal of fixed assets during the year	(34,497)	(392,499)
- tax rate adjustment	2,775,282	-
	(15,651,353)	(21,177,372)
Surplus on revaluation of property, plant and equipment as at 30 June	371,101,820	373,911,368

The freehold land, building and plant and machinery were revalued by independent valuers in years 1976, 1989, 2002, 2006 and 2011 respectively. These revaluations had resulted in a cumulative surplus of Rs. 490 million, which has been included in the carrying values of free hold land, building and plant and machinery respectively and credited to the surplus on revaluation of property, plant and equipment. The surplus is adjusted on disposal of revalued assets, if any, and incremental depreciation, net of deferred tax.

7 Deferred taxation
Taxable temporary difference

	2015		
	Opening	During the year	Closing
	----- Rupees -----		
Accelerated tax depreciation allowances	24,619,261	(133,369)	24,485,892
Surplus on revaluation of property, plant and equipment	21,177,372	(5,526,019)	15,651,353
	<u>45,796,633</u>	<u>(5,659,388)</u>	<u>40,137,245</u>

	2014		
	Opening	During the year	Closing
	----- Rupees -----		

Taxable temporary difference

Accelerated tax depreciation allowances	18,060,264	6,558,997	24,619,261
Surplus on revaluation of property, plant and equipment	23,654,508	(2,477,136)	21,177,372
	<u>41,714,772</u>	<u>4,081,861</u>	<u>45,796,633</u>

	Note	2015 Rupees	2014 Rupees
8 Trade and other payables			
Creditors	8.1	1,037,954,638	245,459,086
Accrued liabilities		16,100,700	17,118,520
Advances from customers		24,653,717	8,432,347
Unclaimed dividend		45,185,439	35,388,721
Provision for compensated absences		14,741,104	6,697,449
Workers' Profit Participation Fund	8.2	62,211,241	33,250,628
Central Research Fund	8.3	11,636,394	6,152,555
Workers' Welfare Fund	28	11,864,141	11,572,956
Advances from employees against purchase of vehicles		18,687,699	17,750,642
Due to subsidiary (unsecured) - Farmacia		3,209,052	4,433,357
Due to subsidiary (unsecured) - BF Biosciences		2,600,513	-
Other payables		1,300,276	1,923,434
		<u>1,250,144,914</u>	<u>388,179,695</u>

8.1 This includes payable to related party, BF BioSciences Limited amounting to Rs. 0.51 million (2014: Rs. Nil).

8.2 Workers' Profit Participation Fund

Balance at the beginning of the year	33,250,628	22,600,594
Interest on funds utilized by the Company	4,611,090	2,804,950
Provision for the year	57,600,151	30,455,148
	<u>95,461,869</u>	<u>55,860,692</u>
Payments made during the year	(33,250,628)	(22,610,064)
	<u>62,211,241</u>	<u>33,250,628</u>

The fund balance has been utilized by the Company for its own business and interest at the rate of 90% (2014: 52.50%) has been credited to the fund. Interest is calculated at higher of 75% of dividend rate or 2.5% plus bank rate, as required under Companies Profits (Workers' Participation) Act, 1968.

	2015 Rupees	2014 Rupees
8.3 Central Research Fund		
Balance at beginning of the year	6,152,555	4,554,728
Provision for the year	11,636,394	6,152,555
	<u>17,788,949</u>	<u>10,707,283</u>
Payments made during the year	(6,152,555)	(4,554,728)
	<u>11,636,394</u>	<u>6,152,555</u>

9 Short term borrowings - secured

The Company has short term borrowing facilities available from various commercial banks under mark up arrangements having aggregate sanctioned limit of Rs. 750 million (2014: Rs. 515 million). These facilities carry mark-up at the rates ranging from three months KIBOR plus 0.1% to 0.9% per annum (2014: three months KIBOR plus 0.3% to 1% per annum) on the outstanding balances. Out of the aggregate facilities, Rs. 450 million are secured by first pari passu charge over present and future current and movable assets of the Company and remaining Rs. 300 million (2014: Rs. 300 million) facility is secured by lien on Company's short term investments in TDR which should be 110% of the maximum limit allowed for utilization. Under this arrangement, Rs. 330 million (2014: Rs. 330 million) is marked under lien. These facilities are renewable on annual basis latest by 30 September 2015.

10 Contingencies and commitments

10.1 Contingencies

10.1.1 Guarantees issued by banks on behalf of the Company

Out of the aggregate facility of Rs. 25 million (2014: Rs. 25 million) for letter of guarantees, the amount utilized at 30 June 2015 was Rs. 2.44 million (2014: Rs. 2.32 million).

10.1.2 The Company has filed a suit before the Honorable High Court of Sindh challenging SRO related to pharmaceutical pricing issued by Drug Regulatory Authority being ultra vires the constitution. The issues relates to fixation of prices of certain products of the Company and the SRO issued in this regard whereby the products of the Company were notified as controlled drugs. The matter is subjudice. However, the management based on obtained legal opinion believes that the Company has a strong case on merit and is likely to succeed in obtaining relief.

10.2 Commitments

10.2.1 Letter of credits

Out of the aggregate facility of Rs. 600 million (2014: Rs. 205 million) for opening letters of credit, the amount utilized at 30 June 2015 for capital expenditure was Rs. 188.75 million (2014: Rs. 24.3 million) and for other than capital expenditure was Rs. 50.57 million (2014: Rs. 112.62 million).

10.2.2 Guarantees issued on behalf of subsidiary companies

The Company has issued cross corporate guarantees of Rs. 218.8 million (2014: Rs.125 million) to Habib Bank Limited, Rs.150 million (2014: Rs. 150 million) to Allied Bank Limited and Rs. 150 million (2014: Nil) to MCB Bank Limited respectively, on behalf of its subsidiary company, BF Biosciences Limited.

11 Property, plant and equipment

	Owned							Capital work-in-progress	Total
	Freehold land	Building on freehold land	Plant and machinery	Office equipment	Furniture and fittings	Computers	Vehicles		
----- Rupees -----									
30 June 2015									
Cost / revalued amount									
Balance as at 01 July 2014	410,000,000	355,135,827	326,015,846	43,792,917	14,222,595	16,926,010	178,042,085	73,823,756	1,417,959,036
Additions	-	-	-	9,298,356	3,080,805	3,468,989	60,796,720	190,042,875	266,687,745
Transfers / adjustments	-	18,945,424	64,016,456	180,133	-	697,116	10,511,500	(94,640,629)	(290,000)
Disposals / write off	-	-	(1,353,834)	(102,700)	-	(1,767,885)	(27,045,573)	-	(30,269,992)
Balance as at 30 June 2015	410,000,000	374,081,251	388,678,468	53,168,706	17,303,400	19,324,230	222,304,732	169,226,002	1,654,086,789
Depreciation									
Balance as at 01 July 2014	-	88,445,667	60,955,702	20,806,789	5,777,525	13,019,468	92,792,428	-	281,777,579
Charge for the year	-	35,961,363	34,595,628	4,403,268	1,583,241	2,946,128	31,748,388	-	111,238,016
On disposals	-	-	(477,916)	(83,858)	-	(1,764,964)	(23,835,661)	-	(26,162,399)
Balance as at 30 June 2015	-	124,407,030	95,053,414	25,126,199	7,360,766	14,200,632	100,705,155	-	366,853,196
Net book value as at 30 June 2015	410,000,000	249,674,221	293,625,054	28,042,507	9,942,634	5,123,598	121,599,577	169,226,002	1,287,233,593
30 June 2014									
Cost / revalued amount									
Balance as at 01 July 2013	410,000,000	340,931,218	299,095,868	53,623,091	20,660,851	24,640,714	162,755,046	18,466,312	1,330,173,100
Additions	-	9,299,901	23,239,057	4,987,512	1,800,958	2,348,970	44,598,099	72,428,201	158,702,698
Transfers / adjustments	-	4,904,708	11,843,151	111,919	-	139,979	71,000	(17,070,757)	-
Disposals / write off	-	-	(8,162,230)	(14,929,605)	(8,239,214)	(10,203,653)	(29,382,060)	-	(70,916,762)
Balance as at 30 June 2014	410,000,000	355,135,827	326,015,846	43,792,917	14,222,595	16,926,010	178,042,085	73,823,756	1,417,959,036
Depreciation									
Balance as at 01 July 2013	-	53,583,728	32,641,346	31,482,001	12,290,059	20,182,381	96,004,616	-	246,184,131
Charge for the year	-	34,861,939	30,658,435	3,897,558	1,503,991	3,040,430	25,539,438	-	99,501,791
On disposals	-	-	(2,364,079)	(14,572,770)	(8,016,525)	(10,203,343)	(28,751,626)	-	(63,908,343)
Balance as at 30 June 2014	-	88,445,667	60,935,702	20,806,789	5,777,525	13,019,468	92,792,428	-	281,777,579
Net book value as at 30 June 2014	410,000,000	266,690,160	265,080,144	22,986,128	8,445,070	3,906,542	85,249,657	73,823,756	1,136,181,457
Depreciation Rate %	-	10	10	10	10	33.33	20	-	-

- 11.1** The last revaluation was carried out on 30 June 2011. Freehold land and building revaluations were carried out under the market value basis whereas plant and machinery were revalued on net replacement cost basis. All the revaluations were carried out by independent valuers.

Had there been no revaluation, carrying value of land, building and plant and machinery would have been as follows:

		Net book value Rupees
Freehold land		75,418,037
Building on freehold land		149,438,481
Plant and machinery		341,689,584
Balance as at 30 June 2015		566,546,102
Balance as at 30 June 2014		546,681,564

	<i>Note</i>	2015 Rupees	2014 Rupees
11.2 Capital work-in-progress - movement			
Opening balance		73,823,756	18,466,312
Additions during the year		190,042,875	72,428,201
Transfers during the year		(94,640,629)	(17,070,757)
Closing balance		169,226,002	73,823,756
11.3 Capital work-in-progress - breakup			
Building and civil works		117,856,079	47,634,312
Plant and machinery		3,475,377	5,088,643
Advances to suppliers		47,894,546	21,100,801
		169,226,002	73,823,756
11.4 Depreciation is allocated as under:			
Cost of sales	24	56,131,949	50,125,174
Administrative expenses	25	29,990,951	27,454,002
Selling and distribution expenses	26	25,115,116	21,922,615
		111,238,016	99,501,791

11.5 Disposal of property, plant and equipment

Particulars of assets	Cost	Net book value	Sale proceeds	Gain / (loss) on disposal	Mode of disposal	Particulars of buyer
-----Rupees-----						
Vehicles disposed off:						
Suzuki Mehran	529,000	52,899	413,000	360,101	Negotiation	Islam Khan
Suzuki Mehran	567,000	132,300	100,000	(32,300)	Negotiation	Aman Ullah Khan
Suzuki Mehran	567,000	170,100	459,000	288,900	Negotiation	Usman Shahid
Suzuki Mehran	567,000	179,550	484,500	304,950	Negotiation	Khalid Rasheed
Suzuki Mehran	567,000	198,450	565,000	366,550	Insurance Claim	EFU Insurance Company
Suzuki Mehran	567,000	207,900	338,000	130,100	Company Policy	Shekeel Shakir
Suzuki Mehran	605,000	221,833	525,000	303,167	Company Policy	Khalil Ahmad
Suzuki Mehran	663,813	354,033	555,000	200,967	Negotiation	Abdul Waqas
Suzuki Mehran	663,813	354,033	525,500	171,467	Negotiation	Khalid Rasheed
Suzuki Mehran	632,000	400,267	635,000	234,733	Insurance Claim	EFU Insurance Company
Suzuki Cultus	985,500	410,625	731,052	320,427	Company Policy	Emanul Ghauri
Vehicles with individual book value not exceeding Rs. 50,000	20,131,447	527,924	10,928,236	10,400,312	Company Policy	Various persons
	27,045,573	3,209,914	16,259,288	13,049,374		
Office equipment disposed off:						
Office equipment with individual book value not exceeding Rs. 50,000	102,700	18,840	42,000	23,160	Company Policy	Vendor
Assets written off:						
Plant and Machinery	1,353,834	875,918	-	(875,918)	Obsolete items-written off	
Computers	1,767,885	2,921	-	(2,921)	Obsolete items-written off	
	3,121,719	878,839	-	(878,839)		
2015 Rupees	30,269,992	4,107,593	16,301,288	12,193,695		
2014 Rupees	70,916,762	7,008,419	13,553,863	6,545,444		

----Rupees----

12 Intangibles

Computer softwares and software licence fees

Cost

Balance at 01 July 2013	5,543,356
Balance at 30 June 2014	5,543,356
Balance at 01 July 2014	5,543,356
Addition during the year	991,131
Transfers	290,000
Balance at 30 June 2015	6,824,487

Amortisation

Balance at 01 July 2013	3,658,647
Amortisation for the year	1,829,328
Balance at 30 June 2014	5,487,975
Balance at 01 July 2014	5,487,975
Amortisation for the year	296,050
Balance at 30 June 2015	5,784,025

Amortisation rate per annum (%)

 --Percentage--
 33.33%

Carrying amounts

-

---Rupees---

At 30 June 2014	55,381
At 30 June 2015	1,040,462

	<i>Note</i>	2015 Rupees	2014 Rupees
--	-------------	------------------------	------------------------

13 Long term investments

Related parties - at cost

Farmacia (Partnership firm)	<i>13.1</i>	89,708,127	75,255,241
BF Biosciences Limited (unlisted subsidiary)	<i>13.2</i>	151,999,960	151,999,960
		241,708,087	227,255,201

13.1 This represents Company's 98% share in "Farmacia", a subsidiary partnership duly registered under the Partnership Act, 1932 and engaged in operating retail pharmacies. Share of profit, if any, for the year not withdrawn is reinvested in capital account of partnership.

13.2 This represents investment made in 15,199,996 ordinary shares of Rs. 10 each, in BF Biosciences Limited.

BF Biosciences Limited has been set up for establishing a Biotech Pharmaceutical Plant to manufacture mainly Cancer and Hepatitis related medicines. The Company holds 80% of equity of the subsidiary and the remaining 20% is held by Laboratories Bagó S.A., Argentina.

	<i>Note</i>	2015 Rupees	2014 Rupees
14 Stores, spare parts and loose tools			
Stores		16,160,950	10,656,769
Spare parts		7,048,932	4,136,133
Loose tools		212,419	184,581
		<u>23,422,301</u>	<u>14,977,483</u>
15 Stock in trade			
Raw material		279,911,865	241,413,478
Work in process		31,321,035	45,827,685
		<u>311,232,900</u>	<u>287,241,163</u>
Finished goods		890,680,428	358,535,743
Less: Provision for write down to net realisable value		-	(517,711)
		<u>890,680,428</u>	<u>358,018,032</u>
Stock in transit		14,678,227	1,360,602
		<u>1,216,591,555</u>	<u>646,619,797</u>
16 Trade debts - considered good			

This includes due from related parties, Farmacia amounting to Rs. 0.14 million (2014: Rs. 0.24 million) and BF Biosciences Limited amounting to Rs. 0.79 million (2014: Rs. 12.15 million).

	<i>Note</i>	2015 Rupees	2014 Rupees
17 Current portion of long term loan			
<u>Related party - considered good</u>			
Loan at beginning of the year	17.1	100,000,000	325,000,000
Less : Receipt during the year		(100,000,000)	(225,000,000)
Amount due within twelve months, shown under current assets		<u>-</u>	<u>100,000,000</u>

17.1 This represented the conversion of overdue mark up and trade receivables from subsidiary company, BF Biosciences Limited into a term loan and rescheduling the payment of overall outstanding term loan in five years with one year grace period starting from 01 July 2010. The conversion was carried out under the authority of a special resolution passed by the Shareholders in the Extraordinary General Meeting held on 14 June 2010, in accordance with the provisions

of Section 208 of the Companies Ordinance, 1984. Mark-up charged on the loan was not less than the borrowing cost of the Company. This loan has been fully recovered during the year.

	Note	2015 Rupees	2014 Rupees
18 Loans and advances - considered good			
Advances to employees - secured	18.1	18,196,445	14,070,254
Advances to suppliers - unsecured		11,949,483	5,287,420
Others		3,413,677	881,470
		<u>33,559,605</u>	<u>20,239,144</u>

18.1 Advances given to staff are in accordance with the Company's policy and terms of employment contract. These advances are secured against provident fund. Advances to staff includes amount due from executives of the Company amounting to Rs. 7.1 million (2014: Rs. 0.55 million).

	Note	2015 Rupees	2014 Rupees
19 Deposits and prepayments			
Deposits		49,342,510	23,945,976
Prepayments		2,153,518	1,148,874
		<u>51,496,028</u>	<u>25,094,850</u>
20 Other receivables			
Due from subsidiary - BF Biosciences Limited		-	41,204
Others		2,629,658	3,925,023
		<u>2,629,658</u>	<u>3,966,227</u>

21 Short term investments

Loans and receivables

Term deposits with banks - local currency	21.1	841,000,000	-
---	------	-------------	---

**Investments at fair value through profit
or loss - listed securities**

Held for trading	21.2	-	718,578,075
		<u>841,000,000</u>	<u>718,578,075</u>

21.1 The local currency short-term deposits have a maximum maturity period of 30 days, carrying profit ranging from 5.92 % to 7.25 % (2014: Nil) per annum.

	Note	2015 Rupees	2014 Rupees
21.2 These investments are 'held for trading'			
Carrying value at 01 July		718,578,075	682,518,656
Redemption during the year		(718,578,075)	-
Unrealized gain on re-measurement of investment - during the year		-	36,059,419
Carrying and fair value of short term investments at 30 June	21.3	<u>-</u>	<u>718,578,075</u>

	Units		Fair value	
	2015	2014	2015	2014
	-----Number-----		-----Rupees-----	
21.3 Mutual fund wise detail is as follows:				
Mutual Funds				
HBL Money Market Fund	-	6,265,634	-	628,578,447
HBL Income Fund	-	147,088	-	14,892,578
MCB DCF Units	-	751,071	-	75,107,050
			<u>-</u>	<u>718,578,075</u>

	Note	2015 Rupees	2014 Rupees
22 Cash and bank balances			
Cash in hand		5,415,184	2,277,375
Cash at bank:			
Current accounts			
- foreign currency		26,784,091	15,592,475
- local currency		305,372,231	86,147,441
		332,156,322	101,739,916
Deposit accounts - local currency	22.1	116,394,723	103,702
		<u>453,966,229</u>	<u>104,120,993</u>

22.1 These carry interest rate ranging from 4.5% - 6.8% per annum on day end balances (2014: 7% - 7.10% per annum).

		2015 Rupees	2014 Rupees
23 Revenue - net			
Gross sales:			
Local		4,428,683,572	2,536,872,092
Export		260,915,635	196,655,904
		4,689,599,207	2,733,527,996
Less:			
Sales returns, discounts and commission		(251,104,466)	(195,969,737)
Sales tax		(4,942,522)	(2,629,934)
		(256,046,988)	(198,599,671)
		<u>4,433,552,219</u>	<u>2,534,928,325</u>

23.1 This includes own manufactured and imported products sales.

	<i>Note</i>	2015 Rupees	2014 Rupees
24 Cost of sales			
Raw materials consumed	24.1	615,955,125	540,133,057
Salaries, wages and other benefits	24.2	119,082,730	98,059,421
Fuel and power		20,609,866	14,838,668
Repair and maintenance		11,011,382	6,030,974
Stores, spare parts and loose tools consumed		17,499,543	15,917,122
Packing charges		21,471,203	14,642,127
Rent, rates and taxes		606,891	1,084,541
Printing and stationery		2,130,360	1,216,992
Postage and telephone		2,462,399	1,957,511
Insurance		1,758,010	5,352,233
Travelling and conveyance		6,079,465	5,089,857
Canteen expenses		6,179,564	5,124,586
Security expenses		3,149,370	2,147,795
Depreciation	11.4	56,131,949	50,125,174
Laboratory and other expenses		10,374,157	10,826,825
		<u>894,502,014</u>	<u>772,546,883</u>
<i>Work in process:</i>			
Opening		45,827,685	23,733,370
Closing		(31,321,035)	(45,827,685)
		<u>14,506,650</u>	<u>(22,094,315)</u>
Cost of goods manufactured		909,008,664	750,452,568
<i>Finished stock:</i>			
Opening		358,018,032	273,111,967
Purchases made during the year		2,041,309,355	565,748,245
Closing		(890,680,428)	(358,018,032)
		<u>1,508,646,959</u>	<u>480,842,180</u>
		<u>2,417,655,623</u>	<u>1,231,294,748</u>
24.1 Raw materials consumed			
Opening		241,413,478	254,880,083
Purchases made during the year		654,453,512	526,666,452
		<u>895,866,990</u>	<u>781,546,535</u>
Closing		(279,911,865)	(241,413,478)
		<u>615,955,125</u>	<u>540,133,057</u>

24.2 Salaries, wages and other benefits include Rs. 4.81 million (2014: Rs. 3.93 million) charged on account of defined contribution plan.

	<i>Note</i>	2015 Rupees	2014 Rupees
25 Administrative expenses			
Salaries and other benefits	25.1	102,469,468	80,350,893
Directors fees and expenses		1,155,848	1,614,955
Rent, rates and taxes		944,249	656,849
Postage and telephone		5,194,081	4,795,256
Printing, stationery and office supplies		2,233,508	2,258,955
Travelling and conveyance		7,354,042	6,819,532
Transportation		6,571,008	4,239,958
Legal and professional charges		3,115,200	4,668,629
Fuel and power		6,903,690	1,643,281
Auditors' remuneration	25.2	995,500	885,500
Repair and maintenance		7,007,370	6,025,799
Fee and subscriptions		1,908,439	1,298,998
Donations	25.3	7,500,000	7,700,000
Insurance		2,789,875	2,511,591
Depreciation	11.4	29,990,951	27,454,002
Amortisation		296,050	1,829,328
Canteen expenses		5,331,359	4,371,384
Other administrative expenses		1,077,236	1,368,235
		<u>192,837,874</u>	<u>160,493,145</u>

25.1 Salaries and other benefits include Rs. 4.04 million (2014: Rs. 3.29 million) charged on account of defined contribution plan.

	2015 Rupees	2014 Rupees
25.2 Auditors' remuneration		
Fee for annual audit	575,000	575,000
Audit of consolidated financial statements	57,500	57,500
Review of half yearly financial statements	86,250	86,250
Special certificates and others	196,250	86,250
Out-of-pocket expenses	80,500	80,500
	<u>995,500</u>	<u>885,500</u>

25.3 Donations were given to "The National Management Foundation", "The Citizen Foundation", "Cancer Research & Treatment Foundation", "The Garage School" and "Lahore Literary Festival". Donations include amount of Rs. 3.5 Million (2014: Rs. 4 million) paid to the National Management Foundation located at DHA Lahore Cantt., where Mr. Osman Khalid Waheed (Director) is one of the trustees and an amount of Rs. 1 million paid to The Garage School located at 96/7 Minerva Court, Clifton Karachi, where Mrs. Zubaida Farooq, wife of Mr. Farooq Mazhar (Non - Executive Director) is member of Executive Board.

	<i>Note</i>	2015 Rupees	2014 Rupees
26 Selling and distribution cost			
Salaries and other benefits	26.1	325,063,945	256,337,274
Travelling and conveyance		135,467,210	118,258,091
Fuel and power		8,843,646	588,727
Rent, rates and taxes		4,648,854	4,042,630
Advertisement and publicity		85,095,384	77,062,286
Freight and forwarding		34,840,445	25,361,685
Printing and stationary		3,875,862	3,606,182
Postage and telephone		12,167,298	8,186,980
Fee and subscription		9,506,634	10,481,430
Insurance		11,734,843	7,988,807
Repairs and maintenance		4,148,530	3,237,571
Legal and professional charges		2,305,458	1,222,950
Conferences, seminars and training		63,787,116	51,095,062
Medical research and patient care		5,819,773	1,495,679
Depreciation	11.4	25,115,116	21,922,615
Other selling expenses		1,570,250	9,244,656
		<u>733,990,364</u>	<u>600,132,625</u>

26.1 Salaries and other benefits include Rs. 10.07 million (2014: Rs. 8.09 million) charged on account of defined contribution plan.

	2015 Rupees	2014 Rupees
27 Finance costs		
Mark-up on bank financing	2,049,373	8,761,224
Bank charges	7,303,816	5,519,546
Interest on Workers' Profit Participation Fund	4,611,090	2,804,950
	<u>13,964,279</u>	<u>17,085,720</u>

	2015 Rupees	2014 Rupees
28 Other expenses		
Workers' Profit Participation Fund	57,600,152	30,455,148
Workers' Welfare Fund	11,864,141	11,572,956
Central Research Fund	11,636,394	6,152,555
	<u>81,100,687</u>	<u>48,180,659</u>

	<i>Note</i>	2015 Rupees	2014 Rupees
29 Other income			
<u>From financial assets</u>			
Profit on deposits with banks		5,477,824	380,584
Exchange gain		7,516,993	15,736,773
Unrealized gain on re-measurement of short term investments to fair value		-	36,059,419
Gain on sale of short term investments		41,027,036	1,278,991
		54,021,853	53,455,767
<u>From related party</u>			
Mark-up on long term loan to subsidiary		5,367,897	26,609,083
Share in profit of Farmacia - 98% owned partnership firm		14,452,886	2,523,125
Others		200,000	200,000
		20,020,783	29,332,208
<u>From non - financial assets</u>			
Gain on sale of property, plant and equipment - net of write off	<i>11.5</i>	12,193,695	6,545,444
Commission income		2,299,015	-
		14,492,710	6,545,444
		88,535,346	89,333,419
30 Taxation			
Current			
- For the year		343,733,734	157,490,198
- Prior years		(6,901,597)	(12,025,446)
		336,832,137	145,464,752
Deferred		(2,884,106)	4,081,861
		333,948,031	149,546,613

30.1 Tax charge reconciliation

	2015 Rupees	2014 Rupees
Numerical reconciliation between tax expense and accounting profit		
Profit before taxation	<u>1,082,538,738</u>	<u>567,074,847</u>
Applicable tax rate as per Income Tax Ordinance, 2001	33%	34%
Tax on accounting profit	357,237,784	192,805,448
Effect of final tax regime	(31,119,051)	(13,017,089)
Effect of tax credit	(8,216,646)	(4,139,002)
Effect of prior year and permanent difference	(8,161,145)	(12,260,202)
Effect of super tax	29,329,198	-
Others (including effect of change in tax rate)	(5,122,109)	(13,842,542)
	<u>(23,289,753)</u>	<u>(43,258,835)</u>
	<u>333,948,031</u>	<u>149,546,613</u>

The Finance Act, 2015 introduced a new tax under Section 5A of the Income Tax Ordinance, 2001 on every public company other than a scheduled bank or modaraba, that derives profits for tax year and does not distribute cash dividend within six months of the end of said tax year or distribute dividends to such an extent that its reserves, after such distribution, are in excess of 100% of its paid up capital. However, this tax on undistributed reserves is not applicable to a public company which distributes profit equal to either 40 percent of its after tax profits or 50% of its paid up capital, whichever is less, within six months of the end of the tax year.

As explained in note 38 to the unconsolidated financial statements, the Board of Directors in their meeting held on 29 August 2015 has recommended a final cash dividend of Rs. 15 per ordinary share which is in addition to interim cash dividend of Rs. 4 per ordinary share for the year ended 30 June 2015 which complies with the above stated requirements. Accordingly, no provision for tax on undistributed reserves has been recognized in these unconsolidated financial statements for the year ended 30 June 2015.

		2015	2014
31 Earnings per share - basic and diluted			
Profit after taxation for distribution to ordinary shareholders	<i>Rupees</i>	<u>748,590,707</u>	<u>417,528,234</u>
Weighted average number of ordinary shares	<i>Numbers</i>	<u>30,186,841</u>	<u>30,186,841</u>
Basic and diluted earnings per share	<i>Rupees</i>	<u>24.80</u>	<u>13.83</u>

31.1 There is no dilutive effect on the basic earnings per share of the Company.

32 Remuneration of Directors, Chief Executive and Executives

	2015		
	Directors	Chief Executive	Executives
	----- Rupees -----		
Managerial remuneration	12,486,501	11,048,664	119,058,229
Utilities	-	453,732	-
LFA	1,071,139	947,796	7,612,104
Bonus	2,846,250	2,518,500	15,776,218
Contribution to provident fund	805,584	761,976	7,226,137
	<u>17,209,474</u>	<u>15,730,668</u>	<u>149,672,688</u>
Numbers	<u>1</u>	<u>1</u>	<u>60</u>
	2014		
	Directors	Chief Executive	Executives
	----- Rupees -----		
Managerial remuneration	19,389,000	10,074,000	94,285,846
Utilities	-	481,684	-
LFA	1,615,750	839,500	5,806,276
Bonus	3,934,000	2,044,000	10,849,656
Contribution to provident fund	1,237,307	687,212	5,559,269
	<u>26,176,057</u>	<u>14,126,396</u>	<u>116,501,047</u>
Numbers	<u>2</u>	<u>1</u>	<u>55</u>

In addition, the Chief Executive, one working directors and certain executives of the Company are allowed free use of the Company's vehicles.

The Company has 4 (2014: 3) non executive directors. Non executive directors are not paid any remuneration or benefits other than the meeting fee and reimbursement of expenses. All the members of the Board of Directors were paid Rs. 310,000 (2014: Rs. 380,000) as meeting fee and Rs. 845,848 (2014: Rs. 1,234,955) as reimbursement of expenses for attending the Board of Directors' meetings.

33 Related party transactions

The Company's related parties include subsidiaries, associated company, entities over which directors are able to exercise influence, staff retirement fund, directors and key management personnel. Balances with the related parties are shown in respective notes in the unconsolidated financial statements. Transactions with related parties are as follows:

	2015 Rupees	2014 Rupees
Farmacia - 98% owned subsidiary partnership firm		
Sale of medicines	1,959,621	1,811,551
Payment received from Farmacia against sale of medicine	2,060,702	1,893,789
Rental	2,767,146	2,515,590
Share of profit reinvested	14,452,886	2,523,125
BF Biosciences Limited - 80% owned subsidiary company		
Recovery of long term loan and mark-up	109,789,598	255,953,247
Mark-up accrued on long term loan	-	4,421,701
Interest on long term loan charged during the year	5,367,897	26,609,083
Sale of finished goods	112,701,591	121,985,268
Payment received	124,066,481	127,844,954
Purchase of goods	897,875	4,156,028
Payment made	4,960,965	4,156,777
Lease rentals	200,000	200,000
Marketing fee	825,529	453,079
Expenses incurred	8,241,585	1,834,828
Cross corporate guarantee (refer note 10)		
Pakistan Pharma Forum - associated company		
Membership fee and annual dues	-	615,174
Khan & Piracha - associated		
Professional services charges	18,000	30,000
Other related parties		
Contribution towards employees' provident fund	18,934,138	15,499,882
Remuneration including benefits and perquisites of key management personnel	89,125,822	78,167,720
Dividend to KFW Factors (Private) Limited	107,730,246	82,869,420
Dividend to directors	49,902,623	42,984,510

34 Plant capacity and production

The production capacity of the Company's plant cannot be determined, as it is a multi-product production facility with varying manufacturing processes.

35 Number of employees

Total number of employees as at 30 June
 Average number of employees during the year

2015	2014
769	687
742	668

Un-audited 2015 Rupees	Audited 2014 Rupees
------------------------------	---------------------------

36 Disclosures relating to provident fund

Size of the fund / trust
 Cost of investments made
 Percentage of investments made %
 Fair value of investment

337,608,183	274,920,772
309,885,764	254,228,842
96%	97%
324,601,757	266,062,022

Break up of investment

Special accounts in scheduled banks
 Term deposit receipts
 Government securities
 Mutual funds
 Shares of listed companies

7,548,093	4,577,808
-	85,197,361
148,182,372	99,358,220
146,604,589	70,143,481
22,266,703	6,785,152
324,601,757	266,062,022

2015	2014
------	------

----- % age of size of fund -----

Break up of investment

Special accounts in scheduled banks
 Term deposit receipts
 Government securities
 Mutual funds
 Shares of listed companies

2%	2%
0%	31%
44%	36%
43%	26%
7%	2%
96%	97%

36.1 The provident fund trust is a common fund for employees of the Group. Entity wise break up of the fund as on 30 June is as follows:

	(Un-audited) 30 June 2015		(Audited) 30 June 2014	
	% of Total Fund	Rupees	% of Total Fund	Rupees
Ferozsons Laboratories Limited - Parent Company	88%	295,871,529	89%	244,074,215
BF Biosciences Limited	11%	37,098,884	10%	27,823,422
Farmacia - Partnership firm	1%	4,637,770	1%	3,023,135
	100%	337,608,183	100%	274,920,772

The figures for 2015 are based on the un-audited financial statements of the Provident Fund. Investments out of Provident Fund have been made in accordance with the provisions of section 227 of the Ordinance and rules formulated for this purpose.

37 Financial risk management

The Company has exposure to the following risks arising from financial instruments:

- Credit risk
- Liquidity risk
- Market risk

This note presents information about the Company's exposure to each of the above risks, the Company's objectives, policies and processes for measuring and managing risk, and the Company's management of capital.

Risk management framework

The Company's Board of Directors has overall responsibility for establishment and oversight of the Company's risk management framework. The Board is responsible for developing and monitoring the Company's risk management policies.

The Company's risk management policies are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company, through its training and management standards and procedures, aims to develop a disciplined and constructive control environment in which all employees understand their roles and obligations. All derivative activities for risk management purposes are carried out by specialist teams that have the appropriate skills, experience and supervision. It is the Company's policy that no trading in derivatives for speculative purposes shall be undertaken. The Board of Directors reviews and agrees policies for managing each of these risks.

The Company's audit committee oversees how management monitors compliance with the Company's risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. Audit committee is assisted in its oversight role by internal audit department. Internal audit department undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the audit committee.

37.1 Credit risk

Credit risk represents the accounting loss that would be recognized at the reporting date if counter parties failed completely to perform as contracted. The Company's credit risk arises from long term deposits, trade debts, other receivables, loans and advances, deposits, short term investments and balances with banks. The Company has no significant concentration of credit risk as its exposure is spread over a large number of counter parties.

37.2 Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the balance sheet date was:

	2015 Rupees	2014 Rupees
Long term loan	-	100,000,000
Long term deposits	3,458,825	3,786,100
Trade debts - considered good	232,931,043	145,664,372
Short term deposits	49,342,510	23,945,976
Other receivables	2,629,658	3,966,227
Mark-up accrued	-	4,421,701
Loans and advances - considered good	21,610,122	14,951,724
Short term investments	841,000,000	718,578,075
Bank balances	448,551,045	101,843,618
	<u>1,599,523,203</u>	<u>1,117,157,793</u>

37.3 Credit quality of financial assets

Bank balances & short term investments

The credit quality of Company's bank balances and short term investments can be assessed with reference to external credit rating agencies as follows:

Institutions	Rating		Rating Agency	2015	2014
	Short term	Long term		----- Rupees -----	-----
Bank balances					
Habib Bank Limited	A-1+	AAA	JCR-VIS	289,382,766	55,868,096
Bank Al-Habib Limited	A1+	AA+	PACRA	78,642,289	-
Bank Alfalah Limited	A1+	AA	PACRA	42,932,424	44,155,448
Habib Metropolitan Bank Limited	A1+	AA+	PACRA	36,185,538	-
Meezan Bank Limited	A-1+	AA	JCR-VIS	726,242	-
MCB bank Limited	A1+	AAA	PACRA	592,958	-
National Bank of Pakistan	A1+	AAA	PACRA	51,031	51,031
Allied Bank Limited	A1+	AA+	PACRA	26,365	1,757,369
Faysal Bank Limited	A1+	AA	PACRA	9,791	10,209
NIB Bank Limited	A1+	AA-	PACRA	1,641	1,465
				<u>448,551,045</u>	<u>101,843,618</u>

Institutions	Rating		Rating Agency	2015	2014
	Short term	Long term		----- Rupees -----	
Short term investments					
Habib Bank Limited - TDR	A-1+	AAA	JCR-VIS	341,000,000	-
Meezan Bank Limited - TDR	A-1+	AA	JCR-VIS	500,000,000	-
HBL Income Fund	-	A(f)	JCR-VIS	-	14,892,578
HBL Money Market Fund	-	AA(f)	JCR-VIS	-	628,578,447
MCB DCF Units	-	A+(f)	PACRA	-	75,107,050
				841,000,000	718,578,025
				1,289,551,045	820,421,693

Trade debts

The aging of trade debts at the reporting date was:

	Related party	Related party	Other	Other
	2015	2014	2015	2014
	Rupees	Rupees	Rupees	Rupees
Past due 0 - 30 days	904,108	1,152,052	87,726,953	50,923,520
Past due 31 - 120 days	23,500	2,320,825	90,768,424	40,531,718
Past due 121 - 365 days	-	8,920,707	44,008,926	28,620,942
More than 365 days	-	-	9,499,132	13,194,608
	927,608	12,393,584	232,003,435	133,270,788

Trade debts are essentially due from government departments / projects and the Company is actively pursuing for recovery of debts and the Company does not expect these companies to fail to meet their obligations.

Loans, deposits and other receivables are mostly due from related parties, employees and Government Institutions. Based on past experience the management believes that no impairment allowance is necessary in respect of these financial assets. There are reasonable grounds to believe that these amounts will be recovered in short course of time.

37.4 Concentration of credit risk

Concentration of credit risk exists when the changes in economic or industry factors similarly affect groups of counterparties whose aggregate credit exposure is significant in relation to the Company's total credit exposure. The Company's portfolio of financial instruments is broadly diversified and all other transactions are entered into with credit-worthy counterparties there-by mitigating any significant concentrations of credit risk.

37.5 Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company's approach to managing liquidity is to ensure as far as possible to always have sufficient liquidity to meet its liabilities when due. The Company is not materially

exposed to liquidity risk as substantially all obligations / commitments of the Company are short term in nature and are restricted to the extent of available liquidity.

The following are the contractual maturities of financial liabilities:

	2015			
	Carrying amount	Less than one year	One to five years	More than 5 years
-----Rupees-----				
<i>Financial liabilities</i>				
Trade and other payables	1,061,165,179	1,061,165,179	-	-
Accrued mark-up	10,634	10,634	-	-
	<u>1,061,175,813</u>	<u>1,061,175,813</u>	<u>-</u>	<u>-</u>

	2014			
	Carrying amount	Less than one year	One to five years	More than 5 years
-----Rupees-----				
<i>Financial liabilities</i>				
Trade and other payables	268,934,397	268,934,397	-	-
Accrued mark-up	3,645,618	3,645,618	-	-
	<u>272,580,015</u>	<u>272,580,015</u>	<u>-</u>	<u>-</u>

37.6 Market risk

Market risk is the risk that changes in market price, such as foreign exchange rates, interest rates and equity prices will effect the Company's income or the value of its holdings of financial instruments.

Market risk comprises of three types of risks:

- currency risk.
- interest rate risk
- other price risk

37.6.1 Currency risk

Pakistani Rupee is the functional currency of the Company and exposure arises from transactions and balances in currencies other than Pakistani Rupee as foreign exchange rate fluctuations may create unwanted and unpredictable earnings and cash flow volatility. The Company's potential currency exposure comprises of:

- Transactional exposure in respect of non functional currency monetary items.
- Transactional exposure in respect of non functional currency expenditure and revenues.

The potential currency exposures are discussed below:

Transactional exposure in respect of non functional currency monetary items

Monetary items, including financial assets and liabilities, denominated in currencies other than the functional currency of the Company are periodically restated to rupee equivalent, and the associated gain or loss is taken to the profit and loss account. The foreign currency risk related to monetary items is managed as part of the risk management strategy.

Transactional exposure in respect of non functional currency expenditure and revenues

Certain operating and capital expenditure is incurred by the Company in currency other than the functional currency. Certain sales revenue is earned in currencies other than the functional currency of the Company. These currency risks are managed as a part of overall risk management strategy. The Company does not enter into forward exchange contracts.

Exposure to currency risk

The Company's exposure to foreign currency risk at the reporting date was as follows:

	2015				
	Rupees	US Dollars	Euro	UAE Dirham	Pound Sterling
Cash and cash equivalents	28,021,796	208,793	58,540	98	945
Trade and other payables	(996,342,147)	(9,806,517)	-	-	-
Trade receivables	61,331,280	397,387	54,054	386,760	-
Balance sheet exposure	<u>(906,989,071)</u>	<u>(9,200,337)</u>	<u>112,594</u>	<u>386,858</u>	<u>945</u>

	2014				
	Rupees	US Dollars	Euro	UAE Dirham	Pound Sterling
Cash and cash equivalents	17,150,692	19,980	111,782	1,198	605
Trade and other payables	(204,533,435)	(2,073,324)	-	-	-
Trade receivables	43,310,445	334,191	76,839	-	-
Balance sheet exposure	<u>(144,072,298)</u>	<u>(1,719,154)</u>	<u>188,621</u>	<u>1,198</u>	<u>605</u>

The following significant exchange rates were applied during the year:

	Balance sheet date rate		Average rate	
	2015	2014	2015	2014
US Dollars	101.60	98.65	101.41	102.80
Euro	113.68	134.60	120.98	139.80
UAE Dirham	27.67	26.86	27.61	27.99
Pound Sterling	159.75	167.96	159.66	168.01

Sensitivity analysis

A 10% strengthening of the Pakistani Rupee against foreign currencies at the reporting date would have increased / (decreased) profit by the amounts shown below. This analysis assumes that all other variables, in particular interest rates remain constant. The analysis is performed on the same basis as for the previous year.

	Profit and loss	
	2015 Rupees	2014 Rupees
Profit and loss account	<u>90,698,907</u>	<u>14,407,230</u>

A 10% weakening of the Pakistani Rupee against foreign currencies at the reporting date would have had the equal but opposite effect on the amounts shown above, on the basis that all other variables remain constant.

37.6.2 Other price risk

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk). The Company is exposed to equity price risk because of investments held by the Company and classified on the Balance Sheet at fair value through profit or loss. To manage its price risk arising from investments in equity securities, the Company diversifies its portfolio within the eligible stocks in accordance with the risk investment guidelines approved by the investment committee.

Sensitivity analysis

The table below summarizes the Company's equity price risk as of 30 June 2015 and 2014 and shows the effects of a hypothetical 10% increase and a 10% decrease in market prices as at the year end. The selected hypothetical change does not reflect what could be considered to be the best or worst case scenarios. Indeed, results could be worse because of the nature of equity markets and the aforementioned concentrations existing in the Company's equity investment portfolio.

	Fair value	"Hypothetical price change"	Estimated fair value after hypothetical change in prices"	"Hypothetical increase (decrease) in profit / (loss) before tax"
-----Rupees-----				
2015				
<u>Short term investments</u>				
Investments at fair value through profit or loss	-	10% increase 10% decrease	- -	- -
	-			
-----Rupees-----				
2014				
<u>Short term investments</u>				
Investments at fair value through profit or loss	718,578,075	10% increase 10% decrease	790,435,883 646,720,267	71,857,808 (71,857,808)
	718,578,075			

37.6.3 Fair value of financial instruments

Fair value is the amount for which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arm's length transaction. The carrying value of all financial assets and liabilities on the balance sheet approximate to their fair value.

a) Fair values versus carrying amounts

The fair values of financial assets and liabilities, together with the carrying amounts shown in the balance sheet are as follows:

	2015		2014	
	Carrying amount	Fair value	Carrying amount	Fair value
-----Rupees-----				
<i>Financial assets</i>				
Long term loan	-	-	100,000,000	100,000,000
Long term deposits	3,458,825	3,458,825	3,786,100	3,786,100
Trade debts - considered good	232,931,043	232,931,043	145,664,372	145,664,372
Short term deposits	49,342,510	49,342,510	23,945,976	23,945,976
Other receivables	2,629,658	2,629,658	3,966,227	3,966,227
Mark-up accrued	-	-	4,421,701	4,421,701
Loans and advances - considered good	21,610,122	21,610,122	14,951,724	14,951,724
Short term investments	841,000,000	841,000,000	718,578,075	718,578,075
Bank balances	448,551,045	448,551,045	101,843,618	101,843,618
	<u>1,599,523,203</u>	<u>1,599,523,203</u>	<u>1,117,157,793</u>	<u>1,117,157,793</u>
<i>Financial liabilities</i>				
Trade and other payables	1,061,165,179	1,061,165,179	268,934,397	268,934,397
Accrued mark-up	10,634	10,634	3,645,618	3,645,618
	<u>1,061,175,813</u>	<u>1,061,175,813</u>	<u>272,580,015</u>	<u>272,580,015</u>

b) Valuation of financial instruments

In case of equity instruments, the Company measures fair value using the following fair value hierarchy that reflects the significance of the inputs used in making the measurements:

Level 1: Quoted market price (unadjusted) in an active market.

Level 2: Valuation techniques based on observable inputs.

Level 3: Valuation techniques using significant unobservable inputs. This category includes all instruments where the valuation technique includes inputs not based on observable data.

Fair values of financial assets that are traded in active markets are based on quoted market prices. For all other financial instruments the Company determines fair values using valuation techniques.

Valuation techniques used by the Company include discounted cash flow model. Assumptions and inputs used in valuation techniques include risk-free rates, bond and equity prices, foreign currency exchange rates, equity and equity index prices. The objective of valuation techniques is to arrive at a fair value determination that reflects the price of the financial instrument at the balance sheet date that would have been determined by market participants acting at arm's length.

Valuation models for valuing securities for which there is no active market requires significant unobservable inputs and a higher degree of management judgement and estimation in the determination of fair value. Management judgement and estimation are usually required for selection of the appropriate valuation model to be used, determination of expected future cash flows on the financial instrument being valued and selection of appropriate discount rates, etc.

The table below analyses equity instruments measured at fair value at the end of the reporting period by the level in the fair value hierarchy into which the fair value measurement is categorised:

30 June 2015	Level 1	Level 2	Level 3	Total
	-----Rupees-----			
Financial assets at fair value through profit or loss	-	-	-	-
30 June 2014				
Financial assets at fair value through profit or loss	718,578,075	-	-	718,578,075

37.6.4 Interest rate risk

Interest rate risk is the risk that the value of a financial instrument will fluctuate due to changes in market interest rates. At the reporting date the interest rate profile of the Company's significant interest bearing financial instruments was as follows:

	2015	2014	2015	2014
	Interest range / Effective rate (in Percentage)		Carrying amount (Rupees)	
Fixed rate instruments				
<u>Financial assets</u>				
Short term investments	5.92 to 7.25	-	841,000,000	-
Net Exposure			841,000,000	-
Variable rate instruments				
<u>Financial assets</u>				
Long term loans	10.29	10.7	-	100,000,000
Cash at bank - deposit accounts	5.65	7.1	116,394,723	103,702
			116,394,723	100,103,702
Net Exposure			116,394,723	100,103,702

Cash flow sensitivity analysis for variable rate instruments

A change of 100 basis points in interest rates at the reporting date would have increased / decreased for the year by the amounts shown below. This analysis assumes that all other variables, in particular foreign currency rates, remain constant. The analysis is performed on the same basis for 2014.

	Profit or loss	
	100 bps Increase	100 bps Decrease
	Rupees	
As at 30 June 2015		
Cash flow sensitivity - Variable rate financial liabilities	1,163,947	(1,163,947)
As at 30 June 2014		
Cash flow sensitivity - Variable rate financial liabilities	1,001,037	(1,001,037)

The sensitivity analysis prepared is not necessarily indicative of the effects on profit for the year and assets / liabilities of the Company.

37.7 Capital management

The Board's policy is to maintain an efficient capital base so as to maintain investor, creditor and market confidence and to sustain the future development of its business. The Board of Directors monitors the return on capital employed, which the Company defines as operating income divided by total capital employed. The Board of Directors also monitors the level of dividends to ordinary shareholders.

The Company's objectives when managing capital are:

- (i) to safeguard the entity's ability to continue as a going concern, so that it can continue to provide returns for shareholders and benefits for other stakeholders, and
- (ii) to provide an adequate return to shareholders.

The Company manages the capital structure in the context of economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may adjust the amount of dividends paid to shareholders, issue new shares, or sell assets to reduce debt.

Neither there were any changes in the Company's approach to capital management during the year nor the Company is subject to externally imposed capital requirements.

38 Non adjusting events after the balance sheet date

The Board of Directors of the Company in its meeting held on 29 August 2015 has proposed a final cash dividend of Rs. 15 per share, for the year ended 30 June 2015, for approval of the members in the Annual General Meeting to be held on 19 October 2015.

39 Date of authorisation for issue

These unconsolidated financial statements have been authorized for issue by the Board of Directors of the Company on 29 August 2015.

Director

Chairperson & Chief Executive